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PREFACE
Since its inception in 2004, the ‘Clinical Practice Guidelines for
the Treatment of Diabetes’ has attempted to promote evidence-
based, rational, efﬁcient and standardized clinical practice for
diabetes in Japan and has undergone revisions every 3 years.
Thus, the current edition represents the ﬁfth revision.
Of note, in recent years, breakthroughs have been made in
the management of diabetes and its complications, which
include the approval of glucose-lowering agents with novel
mechanisms of action for clinical use and the introduction and
adoption of novel diagnostic and therapeutic modalities, such
as continuous glucose monitoring (CGM) and sensor-augmen-
ted insulin pumps (SAP), in clinical practice. Again, renewed
interest in diabetes-associated diseases has led to the accumula-
tion of new evidence, as well as new developments at the Japan
Diabetes Society (JDS), such as ongoing efforts directed toward
the revision of the Classiﬁcation of Diabetic Nephropathy,
ensuring consistency between glucose metabolic disorders and
the diagnostic criteria for diabetes in pregnancy, and establish-
ing glycemic control goals for older patients with diabetes.
Indeed, these developments have gone hand in hand with the
emergence of high-quality evidence from numerous studies
conducted in countries throughout the world, including Japan.
Thus, the current edition aims to incorporate these new
insights and ﬁndings, as well as new lines of evidence, in dia-
betes treatment.
With regard to the revision of the guideline, the current edi-
tion has newly adopted a clinical question (CQ)/question (Q)
format, instead of the ‘statement’ format of the earlier editions,
in the hope that this new format will help improve the ease of
use of the guidelines in clinical practice. The grades of recom-
mendation have also been revised.
It is hoped that the current guidelines will serve as a guide
to implementing evidence-based medicine (EBM) for diabetes
in Japan and thereby contribute to prolonging the longevity
and improving the quality of life (QOL) of patients with dia-
betes.
METHODS FOR DEVELOPING THE ‘JAPANESE CLINICAL
PRACTICE GUIDELINE FOR DIABETES 2016’
The present guideline, which is divided into 21 chapters, con-
sists of important statements intended to assist in clinical prac-
tice, which are also intended as recommendations. These
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SPECIAL REPORT
statements were developed separately as general questions and
clinical questions based on published clinical evidence as well
as expert consensus.
This guideline offers key recommendations for clinical prac-
tice that are supported by scientiﬁc evidence from published
studies. Studies of interest were obtained by a systematic
search of the English and Japanese literature. The electronic
databases used for literature search included at least MED-
LINE and the Japanese ICHUSHI database (http://www.jamas.
or.jp/). The search strategies used were developed by each
author. The studies of interest were critically appraised by the
authors to determine their relevance to the statements of the
guideline and whether they were worth citing. Each study was
assigned a level of evidence using the approach described in
Table 1.
Each statement for the CQs was assigned a grade of recom-
mendation based on the total body of evidence as well as the
risk-beneﬁt balance, value, patient preferences, cost, and
resources. Statements were graded as A (strongly recom-
mended) or B (recommended), followed by the agreement rate
among authors. Grade A or B by consensus reﬂects a recom-
mendation based solely on the consensus of professionals and
indicates that the recommendation was adopted with a ≥70%
agreement rate among the authors.
A summary table, including an identiﬁer, the research design,
the level of evidence and population, methods, and results of
the cited articles was attached at the end of each chapter in the
original Japanese version (The Japan Diabetes Society: Japanese
Clinical Practice Guideline for diabetes 2016. Tokyo: Nankodo,
2016.). Scientiﬁc reports supporting a statement were cited as
‘References’ and additional guidelines or review articles were
listed as ‘Additional reference materials’.
The guideline will be reviewed every 3 years, as there will be
considerable advances in clinical research and practice that will
require a re-evaluation of the scientiﬁc evidence as it becomes
available. All potential conﬂicts of interest were disclosed by
authors.
1 GUIDELINE FOR THE DIAGNOSIS OF DIABETES
MELLITUS
Q1-1 How is diabetes diagnosed? (Figure 1)
• The diagnosis of diabetes mellitus should be as comprehen-
sive as possible. It is conﬁrmed by the presence of chronic
hyperglycemia, and by the presence of other factors, such as
associated symptoms, clinical laboratory ﬁndings, a family
history of diabetes, and the patient’s body weight history1–5.
For the diagnosis of diabetes, either of the following
approaches is to be followed:
① Two assessments of the diabetic type in each patient
(one blood glucose test is mandatory).
② One assessment of the diabetic type (with mandatory
blood glucose testing) along with the presence of
chronic hyperglycemic symptoms*. (*typical symp-
toms of chronic hyperglycemia (e.g., dry mouth, poly-
posia, polyuria, body weight loss, or diabetic
retinopathy).
③ Evidence of a prior diagnosis of ‘diabetes’.
Q1-2 How is hyperglycemia assessed? (Figure 2)
• Patients are to be classiﬁed into the normal type, borderline
type, or diabetic type, based on the combination of fasting
and 2-h post-75 g oral glucose tolerance test (OGTT) glu-
cose values.
• Patients whose fasting glucose values are 100–109 mg/dL
(5.6–6.1 mmol/L) are classiﬁed into the ‘high normal’ cate-
gory as part of the normal type6.
• The OGTT is to be proactively considered in high-risk indi-
viduals (i.e., those who are suspected to have diabetes or the
borderline type, those whose fasting glucose values are
shown to be ‘high-normal’, those with HbA1c values of
≥5.6%, those with obesity or dyslipidemia, and those with a
strong family history of diabetes5).
• At present, HbA1c values measured by point-of-care testing
(POCT) devices are not to be used for the diagnosis5.
Q1-3 How should individuals who are shown to be the
diabetic type in an initial glucose/HbA1c assessment but who
not on subsequent assessments be managed?
• When the diagnosis is not conﬁrmed by repeated assess-
ments, glucose measurements and OGTTs should be





1+ High-quality* randomized controlled trials (RCTs)
Meta-analysis or systematic review of trials with level 1+
1 RCTs that fail to meet level 1+ evidence
Meta-analysis or systematic review of trials with level 1
2 Prospective cohort studies, or meta-analysis or systematic
review of them
Pre-specified sub-analyses of RCTs
3 Non-randomized controlled trials
Self-controlled (before-after) studies
Retrospective cohort studies
Case–control studies, or meta-analysis or systematic review
of them
Post-hoc sub-analyses of RCTs
4 Cross-sectional studies
Case-series
*A high-quality RCT was defined as a trial that was appropriately
designed and conducted with a large sample size and a clearly speci-
fied randomization scheme, involving double masking and a high fol-
low-up rate.
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performed every 3 to 6 months to monitor their clinical
course5.
• If the glucose value on the initial assessment was found to
be ≥200 mg/dL (11.1 mmol/L) by a casual blood glucose
measurement, it would be preferable to use other tests on
the subsequent conﬁrmatory assessments5.
• In principle, conﬁrmatory assessments should involve both
HbA1c and blood glucose measurements. The diagnosis
must be made with close attention given to their blood glu-
cose values, particularly in patients with any disease or con-
dition that is likely to result in disparity between the HbA1c
level and the mean glucose value5.
Q1-4 How is diabetes classiﬁed into its types? (Table 2)
• The classiﬁcations of diabetes are to be primarily described
according to the etiology (mechanism), and additionally
according to the pathophysiological state (stage) based on
the insufﬁciency of insulin action (See Q1-7 for the relation-
ship between their etiology and pathophysiology).
• Diabetes and other glucose metabolic disorders are to be
classiﬁed into four categories: (I) type 1 diabetes, (II) type 2
diabetes, (III) other types due to speciﬁc pathophysiological
mechanisms or diseases, and (IV) gestational diabetes
(GDM). At present, all forms of diabetes or other glucose
metabolic disorders that fail to be classiﬁed as any of the
above are to be classiﬁed as ‘unclassiﬁable’5.
• The etiological factors of patients should be assessed with
attention to various types of clinical information such as the
family history, age at the onset of diabetes and clinical
course, physical characteristics, islet autoantibodies, human
leukocyte antigen (HLA), insulin-secretory capacity/severity
of insulin resistance, and genetic test results5.
• Individual patients may have multiple etiological factors5.
Diabetic Type
Both plasma glucose level and
















– Typical symptoms of diabetes mellitus
– Deﬁnite diabetic retinopathy




































Figure 1 | Flow chart outlining the steps in the clinical diagnosis of diabetes mellitus. OGTT, Oral glucose tolerance test. [Colour figure can be
viewed at wileyonlinelibrary.com]
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Q1-5 How is type 1 diabetes (including acute, slowly-
progressive, and fulminant forms of type 1 diabetes)
diagnosed? (Table 3)
• Type 1 diabetes is classiﬁed by the etiology as (A) autoim-
mune and (b) idiopathic and also classiﬁed by the manner
of the disease onset as acute, slowly-progressive, and fulmi-
nant.
• Patients with acute type 1 diabetes are generally likely to
develop ketosis or ketoacidosis within 3 months of the onset
of hyperglycemia and required insulin therapy immediately7.
• Patients with slowly progressive (insulin-dependent) type 1
diabetes do not develop ketosis or ketoacidosis and do not
require insulin therapy immediately, although their diagnosis
is established by a positive test for anti-GAD antibodies or
islet cell antibodies (ICA)8.
• Patients with fulminant type 1 diabetes frequently develop
ketosis or ketoacidosis within 1 week of the onset of hyper-
glycemia, require insulin therapy immediately, and are char-
acterized by having lower HbA1c values relative to their
glucose values9.
Q1-6 How is diabetes due to other speciﬁc pathophysiological
mechanisms or diseases diagnosed?
• Recent advances in gene analysis techniques have led to a
number of single gene abnormalities being identiﬁed as
causes of diabetes. These are generally divided into ① those
related to the pancreatic b-cell function and ② those related
to the mechanisms of insulin action.
• A diabetic condition may occasionally be a part of various
diseases, syndromes and pathologies. Some of these were for-
merly called ‘secondary diabetes’ and include forms of dia-
betes associated with pancreatic, endocrine and hepatic
diseases, drug use, exposure to chemicals, viral infections,
and an array of genetic syndromes.
• Gestational diabetes mellitus (GDM) refers to a form of glu-



















Figure 2 | The categories of glycemia as indicated by fasting plasma glucose levels and 75 g OGTT results. *1 The impaired fasting glucose (IFG)
category represents cases of fasting plasma glucose levels of 110–125 mg/dL (6.1–7.0 mmol/L) and 2-h plasma glucose levels of <140 mg/dL
(7.8 mmol/L) in a 75 g OGTT (WHO). However, in the ADA criteria, IFG is defined as a fasting plasma glucose levels of 100–125 mg/dL (5.6–
7.0 mmol/L), and only FPG is used for the determination of IFG. *2 Fasting plasma glucose levels of 100–109 mg/dL (5.6–6.1 mmol/L) are within
the normal limits, but are considered to be ‘high-normal’. Because patients with a high-normal glucose level are at risk of developing diabetes and
include cases with various degrees of impaired glucose tolerance, the performance of an OGTT is desirable. *3 The category was adopted by the
WHO in the diagnostic criteria for diabetes mellitus, and represents cases with fasting plasma glucose levels of <126 mg/dL and 2-h plasma
glucose levels of 140–199 mg/dL (7.8–11.1 mmol/L in a 75 g OGTT.
Table 2 | Etiological classification of diabetes mellitus and glucose
metabolism disorders




II. Type 2 (ranging from predominantly insulin secretory defect to
predominantly insulin resistance with varying degrees of insulin
secretory defect)
III. Due to other specific mutation or diseases
A. Those in which specific mutations have been identified as cause of
genetic susceptibility
(1) Genetic abnormalities of pancreatic b-cell function
(2) Genetic abnormalities of insulin action
B. Those associated with other diseases or conditions
(1) Diseases of exocrine pancreas
(2) Endocrine disease
(3) Liver disease
(4) Drug- or chemical-induced
(5) Infections
(6) Rare forms of immune-mediated diabetes
(7) Various genetic syndromes often associated with diabetes
IV. Gestational diabetes mellitus
The occurrence of diabetes specific complications has not been con-
firmed in some of these conditions. Those that cannot currently be
classified as any of the above are considered unclassifiable.
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the ﬁrst time during pregnancy and does not reach the crite-
ria of overt diabetes.
• The diagnosis of these forms of diabetes requires a close
review of relevant clinical data, which include: ① family his-
tory and mode of inheritance;② age at the onset of diabetes
and clinical course; ③ other physical characteristics; and
④ islet autoantibodies.
Q1-7 How do the types of diabetes (their etiology) each relate
to their respective pathophysiology (clinical stage)? (Figure 3)
• Their etiology (mechanism) and pathophysiological states
(stages) represent dimensions distinct from each other and
both should be used to describe the condition in each indi-
vidual patient.
• Whatever the underlying etiology, diabetes may develop
through various physical conditions and its pathophysiology
may change with the treatment.
• Pathophysiological states (stages) of diabetes are to be differ-
entiated into the following three stages based on the insufﬁ-
ciency of insulin action: ① not requiring insulin therapy;
② requiring insulin therapy for glycemic control; and③ re-
quiring insulin therapy to prevent ketosis and to support/sus-
tain life.
• Insulin-dependent state refers to the life-threatening status in
which patients who do not receive exogenous insulin are
prone to ketosis. In contrast, non-insulin dependent state
refers to a state in which insulin injection is required not to
prevent ketosis or to support/sustain life but to ameliorate
glycemic control. Thus, patients receiving insulin therapy are
not always in an insulin-dependent state.
2 GOALS AND STRATEGIES FOR DIABETES
MANAGEMENT
Q2-1 What are the objectives of diabetes management?
• The objectives of diabetes management are to improve meta-
bolic dysfunctions resulting from hyperglycemia, to prevent
the development or progression of diabetic complications and
conditions associated with diabetes, and to enable affected
individuals to maintain their quality of life (QOL) and life
expectancy comparable to those of healthy individuals.
Q2-2 How is a basic diabetes treatment strategy developed
for each patient? (Figure 4)
• The treatment strategy for diabetes may vary depending on
the type, disease condition, age, metabolic abnormality, and
status of diabetic complications.
• Insulin therapy is to be given not only to patients who are
insulin-dependent but also to pregnant patients, patients
undergoing surgery that involves whole-body management,
and patients with severe infection, even if they are not insu-
lin-dependent. In addition, insulin therapy is to be given to
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hypoglycemic agents (OHAs) or glucagon-like peptide 1
(GLP-1) receptor agonists.
• OHA and/or GLP-1 agonist therapy is to be given to non-
insulin-dependent patients in whom favorable glycemic con-
trol is not achievable with adequate medical nutrition ther-
apy (MNT) and physical activity/exercise continued for 2–
3 months. OHA and/or GLP-1 agonist therapy or insulin
therapy may be given to these patients from the outset
depending on the severity of the metabolic disorder involved.
• Continued therapy is essential for patients with diabetes to
prevent the onset or progression of complications. Team
care-based diabetes education for these patients forms the
cornerstone of their diabetes treatment.
Q2-3 How is the glycemic goal set for each individual patient?
(Figure 5)
• Glucose levels in affected individuals should be controlled as
close to normal as possible. Achieving and maintaining favor-
able glycemic control early after initiation of treatment is likely
to lead to favorable long-term outcomes in these individuals1.
Q2-4 How is the onset of chronic diabetic complications
prevented or their progression delayed?
• Diabetes management is aimed not merely at glycemic con-
trol1 but also at ensuring continued smoking cessation and
control of blood pressure and lipid levels, thereby preventing
chronic diabetic complications or delaying their progres-
sion2,3.
3 MEDICAL NUTRITION THERAPY (MNT)
Q3-1 What is the role of MNT and the optimal nutritional
balance in MNT for patients with diabetes?
• Carbohydrates, proteins and fats should account for 50–60%,
≤20%, and 20–30%, respectively, of the total energy intake in
MNT for patients with diabetes.
• The ratios of macronutrients may vary depending on physi-
cal activities and the severity of diabetic complications, as
well as on the food preferences of each patient with diabetes.
CQ3-2 Is MNT education by registered dieticians effective?
• MNT education by registered dieticians is effective1,2.
(Grade A: 100% agreement)
Q3-3 What is the ideal body weight (IBW) and how is the
total energy intake determined for each patient with
diabetes?
• The goal of MNT for patients with type 2 diabetes is to opti-
mize their total energy intake, thereby helping them main-
















Arrows pointing right represent worsening of glucose metabolism disorders (including onset of diabetes
mellitus). Among the arrow lines,
mellitus”. Arrows pointing left represent improvement in the glucose metabolism disorder. The broken
lines indicate events of low frequency.
Borderline area
and indicate the condition classiﬁed as “diabetes
Figure 3 | A schematic diagram of the relationship between the etiology (mechanism) and pathophysiological stages (states) of diabetes mellitus.
Arrows pointing right represent the worsening of glucose metabolism disorders (including the onset of diabetes mellitus). Among the arrow lines,
indicates the condition classified as ‘diabetes mellitus’. Arrows pointing left represent improvement in the glucose metabolism disorder. The broken
lines indicate events of low frequency. For example, in type 2 diabetes mellitus, infection can lead to ketoacidosis and require temporary insulin
treatment for survival. Also, once diabetes mellitus has developed, it is treated as diabetes mellitus regardless of the improvement in the glucose
metabolism; thus, the arrow lines pointing left are filled in black. In such cases, a broken line is used, because complete normalization of the
glucose metabolism is rare. [Colour figure can be viewed at wileyonlinelibrary.com]
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•  Applicable to most cases of type 2 diabetes  •  Without acute metabolic disorder
•  Casual plasma glucose levels approximately 250 ~ 300 mg/dL or lower
•  Negative urinary ketone bodies
The target for glycemic control is established for each patient by the physician-in-charge,
taking into account the patient’s age and the condition.
Start of treatment (First consultation)
•  Education of patients regarding diet therapy, exercise therapy, improvement
   of lifestyle 
•  Education of patients regarding diet therapy, exercise therapy, improvement
   of lifestyle 
•  Education of patients regarding diet therapy, exercise therapy, improvement
   of lifestyle 
•  Education of patients regarding diet therapy, exercise therapy, improvement
   of lifestyle 
•  Intensive insulin treatment
•  Treatment with increased dose of oral hypoglycemic agent, or their combination
•  Switch to insulin or to an oral hypoglycemic agent in combination treatment with
   insulin
•  Switch to a GLP-1 receptor agonist or an oral hypoglycemic agent or insulin in
   combination with a GLP-1 receptor agonist
•  Treatment with oral hypoglycemic agents
•  Insulin treatment
•  Treatment with GLP-1 receptor agonist
Achievement of target for
glycemic control
Achievement of target for
glycemic control










































Figure 4 | Treatment of patients in a non-insulin-dependent state. This provides a guide to the management of patients without acute metabolic
disorder (i.e., those who had a casual blood glucose level of 250–300 mg/dL [13.9–16.7 mmol/L] or less than 250 to 300 mg/dL with a negative
urinary ketone test). The glycemic goal should be determined individually depending on the disease condition or age of the patient but is
generally set at HbA1c <7.0%. ‘Diet therapy’ and ‘exercise therapy’ are referred to as ‘medical nutrition therapy (MNT)’ and ‘physical activity/exercise’,
respectively, elsewhere in this guideline. [Colour figure can be viewed at wileyonlinelibrary.com]
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For each patient with type 2 diabetes, the IBW is to be cal-
culated consistent with a body mass index (BMI) value of 22,
and his/her total energy intake is to be calculated by the follow-
ing equations:
Total energy intake (kcal/day) = IBW (kg) 9 physical activ-
ity (kcal/kg IBW/day).
IBW (kg) = (height [m])2 9 22.
Physical activity (kcal/kg IBW/day) =
25–30: light physical activity (e.g., jobs mainly involving desk
work),
30–35: moderate physical activity (e.g., jobs mainly involving
standing work),
>35: heavy physical activity (e.g., jobs mainly involving
heavy physical labor).
• It is less practical to uniformly aim for the IBW in all
patients with type 2 diabetes, irrespective of their initial BMI
values. Rather, given that the body weight reﬂects the energy
balance, it is advised to aim for a 5% reduction in body
weight in obese individuals with type 2 diabetes; and to aim
for the IBW, depending on its possible improvement of
metabolic conditions or its feasibility.
Q3-4 How does the dietary carbohydrate intake affect
diabetes management?
• No relationship has been shown between the carbohydrate
intake, the risk of diabetes, and glycemic control.
• The consumption of sucrose-containing sweets and juices is
not advised, given that they may worsen glycemic control
and lead to metabolic syndrome.
• Patients should limit their intake of fruits up to one unit at
a time.
※In Japan, a common serving size is 80 kcal or a multiple
thereof. Thus, 80 kcal is set as 1 unit for discussing amounts
of nutrients in MNT.
• The effects of artiﬁcial sweeteners on glycemic control have
not been fully investigated.
• Instructions on carbohydrate counting are effective in helping
patients on insulin therapy achieve optimal glycemic control.
Q3-5 How does the dietary ﬁber intake affect diabetes
management?
• Given that dietary ﬁber has been shown to be effective in
improving diabetic states, patients with diabetes are encour-
aged to consume ≥20 g of dietary ﬁber daily, irrespective of
their carbohydrate intake.
• No evidence is available to support food choice based on the
glycemic index (GI) in diabetes management.
Q3-6 How does the dietary protein intake affect diabetes
management?
• There is no evidence to demonstrate that an increased pro-
tein intake is associated with an increased risk of diabetic
nephropathy.
• An intake that accounts for ≥20% of the total energy intake
may increase the risk of mortality from any cause including
atherosclerosis and the risk of diabetes. No evidence is avail-
able to support the long-term safety of the practice.
Q3-7 How does the dietary fat intake affect diabetes
management?
• While no clear relationship has been shown between the
total dietary fat intake and the risk of diabetes, an increased
Control target values *4
HbA1c (%)
Target
Target when aiming for
normal glycemia *1
Target when aiming




< 6.0 < 7.0 < 8.0
Figure 5 | Glycemic control targets. Control targets are established individually, in consideration of age, duration of disease, organ damage, risk of
hypoglycemia, support structures, etc. *1 When targets can be attained by appropriate MNT or physical activity/exercise, or during
pharmacotherapy without the occurrence of side effects such as hypoglycemia. *2 From the perspective of preventing complication, HbA1c target
value is set at <7%. A fasting blood glucose level <130 mg/dL (7.2 mmol/L) and a 2-h postprandial blood glucose level <180 mg/dL (10.0 mmol/
L) can be used as an approximate guideline for the corresponding blood glucose levels. *3 When intensification of treatment is considered difficult
due to side effects such as hypoglycemia or for other reasons. *4 All target values are for adults, not including pregnant women. [Colour figure
can be viewed at wileyonlinelibrary.com]
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saturated fatty acid (SFA) intake has been shown to be asso-
ciated with the risk of diabetes.
• The dietary fat intake should account for 20–30% of the total
energy intake (SFA, ≤7%) in patients with diabetes. When it
accounts for >25%, care needs to be taken to modify the
fatty acid composition by reducing the SFA intake.
• No evidence is available to support the beneﬁts of n-3 fatty
acids in diabetes management.
Q3-8 How does the dietary vitamin and mineral intake affect
diabetes management?
• No clear relationship has been shown between the dietary
vitamin and mineral intake and diabetes.
Q3-9 How does the dietary salt intake affect diabetes
management?
• Dietary salt restriction has been shown to be useful for
reducing the risk of cardiovascular disease in inadequately
controlled diabetes.
Q3-10 When is the consumption of alcohol allowable in
patients with diabetes?
• The alcohol intake is to be individualized for each patient
with 20–25 g of absolute ethanol equivalent daily as a mea-
sure of the upper limit. At present, the differences in how
different types of alcoholic beverage impact diabetes manage-
ment remain unclear; however, attention needs to be paid to
carbohydrate-derived energy in low-malt beers. The intake of
alcohol may lead to an acute episode of hypoglycemia in
patients receiving sulfonylurea (SU) or insulin therapy, and
it therefore needs to be closely monitored. Biguanides, which
are known to cause lactic acidosis, are contraindicated in
individuals whose intake of alcohol is excessive. However,
the consumption of alcohol may be allowable, if it is kept
reasonable individuals whose diabetes is well controlled and
who are capable of self-managing potential problems associ-
ated with the intake of alcohol.
4 PHYSICAL ACTIVITY/EXERCISE
Q4-1 Is a medical check-up required before implementing
physical activity/exercise?
• Prior to implementing physical activity/exercise in a patient
with diabetes, the patient needs to be evaluated for the pres-
ence and severity of cardiovascular disease, peripheral/auto-
nomic neuropathy, advanced retinopathy, nephropathy, and
orthopedic diseases1.
• Screening for cardiovascular disease is recommended for
asymptomatic patients with multiple risk factors, those with
cerebrovascular or peripheral atherosclerotic disease, those
with electrocardiographic evidence of ischemia, and those
undertaking high-intensity exercise2.
Q4-2 Is exercise effective for patients with type 2 diabetes?
• Aerobic exercise is associated with improvements in glyce-
mic control3, insulin resistance, cardiopulmonary function4,
and lipid metabolism5, as well as reductions in blood
pressure.
(Grade A: 100% agreement)
• Both aerobic and resistance exercise are effective for improv-
ing glycemic control, and are even more effective when com-
bined6.
(Grade A: 100% agreement)
CQ4-3 Is exercise effective for patients with type 1 diabetes?
• While there is no consensus on the effects of exercise on
long-term glycemic control7,8, exercise is associated with a
reduced risk of cardiovascular disease and improved quality
of life (QOL).
(Grade B: 100% agreement)
Q4-4 What are aerobic and resistance exercise?
• Aerobic exercise is deﬁned as exercise involving a sufﬁcient
supply of oxygen and adenosine triphosphate (ATP) resyn-
thesized through reactions between carbohydrates and
lipids as its substrates as energy sources, and continuous
rhythmical and repeated movements of the major skeletal
muscles lasting for 10 min or longer. Aerobic exercises
enhance the cardiopulmonary function. Resistance exercises
involve skeletal muscle loading and are performed to
enhance the muscular function (muscle strength and
endurance).
Q4-5 How should an exercise regimen be implemented in
practice?
• It is generally recommended that exercise involving moder-
ate-intensity aerobic exercise lasting for 20–60 min each time
or a total of ≥150 min per week be implemented on a daily
basis (preferably), or at least 3–5 times a week. It is also rec-
ommended that resistance exercise be implemented 2–3
times a week concurrently with aerobic exercise1.
• It is advisable to increase the intensity and amount of exer-
cise in a stepwise fashion and to include warm-ups and
cool-downs before and after exercise in daily life. It is also
advisable to examine both feet closely and to use properly
ﬁtting cushioned shoes.
• Patients receiving insulin or glucose-lowering agents (SUs
in particular) may experience episodes of hypoglycemia
during exercise, on the day of exercise, or on the day after
exercise. It is therefore recommended that patients receiving
insulin adjust the duration, type and amount of exercise
being performed and the doses of drugs being used (as a
rule, a dose reduction of ultra-fast-acting insulin before
exercise) and to eat as required before and during exercise
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through the self-monitoring of blood glucose (SMBG). It is
especially recommended that patients receiving insulin con-
sume one to two units of easily absorbed carbohydrates
before exercise if their pre-exercise glucose level is below
100 mg/dL (5.6 mmol/L)1.
• Patients who are in good physical condition may not need
to discontinue exercise simply due to hyperglycemia; how-
ever, patients with type 1 diabetes and urine ketone bodies
should refrain from exercise9.
5 TREATMENT WITH GLUCOSE-LOWERING AGENTS
(EXCLUDING INSULIN)
Q5-1 What are the indications for glucose-lowering agents?
• Glucose-lowering agents are indicated for patients with non-
insulin-dependent stages of diabetes who fail to achieve
favorable glycemic control with adequate MNT and/or physi-
cal activity/exercise of 2–3 months in duration1–3. However,
glucose-lowering agents, including insulin, are indicated,
along with MNT and/or physical activity/exercise, for
patients in non-insulin-dependent stages who require the
elimination of glucotoxicity.
• The absolute indications for insulin therapy include type 1
diabetes, pregnancy complicated by diabetes not amenable to
control by MNT alone, diabetic coma, severe infection, sur-
gery requiring whole-body management In these cases, glu-
cose-lowering agents are not indicated and insulin therapy
should be initiated immediately.
Q5-2 How are glucose-lowering agents chosen for diabetes
treatment?
• The choice of glucose-lowering agents should be individual-
ized for each patient according to the disease condition, with
attention also given to their pharmacological and safety pro-
ﬁles. With informed consent obtained from the patient, the
drug(s) should be initiated at a low dose and gradually
titrated upwards as required depending on the glycemic con-
trol of the patient at that time.
Q5-3 What are the characteristics of sulfonylureas (SUs)?
• Sulfonylureas (SUs) potently lower blood glucose level
through their ability to promote the secretion of insulin from
pancreatic b cells and current evidence demonstrates their
usefulness in reducing microangiopathy3. SUs have been
shown to readily exert their effects in patients with preserved
insulin capacity; however, they have often been shown to be
associated with the side effect of hypoglycemia. SUs are also
associated with weight gain in patients who are less adherent
to MNT and/or physical activity/exercise4.
Q5-4 What are the characteristics of biguanides?
• Biguanides are currently used as ﬁrst-line glucose-lowering
agents in Western countries. Biguanides exert their effect
by inhibiting hepatic glucose production as well as by
improving peripheral insulin sensitivity. Current evidence
demonstrates their usefulness in reducing macroangiopathy
in patients with type 2 diabetes5–8. Although they are rarely
associated with lactic acidosis, caution needs to be taken to
determine whether the patient can be safely treated with
biguanides.
Q5-5 What are the characteristics of a-glucosidase inhibitors?
• a-glucosidase inhibitors, which inhibit intestinal glycolysis
and delay intestinal glucose absorption, suppress postprandial
hyperglycemia and hyperinsulinemia and should be taken
immediately before meals; they are also often associated with
ﬂatus and diarrhea. Hypoglycemia in patients treated with
these agents can be effectively improved with the ingestion
of only glucose.
Q5-6 What are the characteristics of thiazolidinediones (TZDs)?
• Thiazolidinediones (TZDs) improve glycemic control by pro-
moting peripheral insulin sensitivity and inhibiting hepatic
glucose release; they are also often associated with weight
gain due to their ability to promote ﬂuid retention and adi-
pocyte differentiation. Patients receiving TZDs require moni-
toring for edema, anemia and fracture associated with the
use of TZDs9–13.
Q5-7 What are the characteristics of glinides?
• Glinides correct postprandial hyperglycemia by immediately
promoting insulin secretion, with their action diminishing in
such a short time that they are less associated with the risk
of hypoglycemia.
Q5-8 What are the characteristics of DPP-4 inhibitors?
• DPP-4 inhibitors glucose-dependently promote postprandial
insulin secretion while at the same time inhibiting glucagon
secretion, thus improving both fasting and postprandial
hyperglycemia. While the risk of hypoglycemia with DPP-4
inhibitor monotherapy is small, combination therapy with
an SU or insulin often increases the risk of hypoglycemia,
suggesting the rationale for reducing the dose of either part-
nering agent14–18.
• DPP-4 inhibitors were previously thought to be associated
with the risk of acute pancreatitis, pancreatic cancer or infec-
tions; however, current evidence appears to argue against
this19. They are not associated with an increased risk of
macroangiopathy20–22. Thus, at present, DPP-4 inhibitors
appear to have a favorable safety proﬁle.
Q5-9 What are the characteristics of GLP-1 receptor agonists?
• GLP-1 receptor agonists, which are available as injectable
agents, promote postprandial insulin secretion in a glucose-
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dependent manner while at the same time inhibiting glucagon
secretion; thus they improve both fasting and postprandial
hyperglycemia and are less associated with a risk of hypo-
glycemia. While these agents have also been shown to exert
their glucose-lowering effect in combination with an SU or
insulin, this combination therapy has been shown to be associ-
ated with an increased risk of hypoglycemia, suggesting the
rationale for reducing the dose of either partnering agent23,24.
• GLP-1 receptor agonists are associated with gastrointestinal
symptoms. Thus, to alleviate the onset of such symptoms,
GLP-1 receptor agonists need to be initiated at a low dose
and titrated upwards as required. Current evidence suggest
that these agents are not associated with a risk of acute pan-
creatitis25; their cardiovascular safety has also been demon-
strated26.
Q5-10 What are the characteristics of SGLT2 inhibitors?
• SGLT2 inhibitors inhibit glucose reabsorption in the proxi-
mal renal tubule and promote urinary glucose excretion, thus
exerting their glucose-lowering effect; they not only improve
glycemic control independently of insulin-mediated mecha-
nisms but also associated with body weight reduction.
• Among the SGLT2 inhibitors, empagliﬂozin has been shown
to signiﬁcantly delay the onset of cardiovascular events in
patients at high risk for these events27.
• SGLT2 inhibitors are associated with an increased frequency
of urinary tract infections and genital infections as adverse
effects27–29. Other adverse effects include dehydration accom-
panied by symptoms such as thirst, polyuria, pollakiuria, or
hypotension, dehydration-associated thromboembolism
including cerebral infarction, events associated with increased
ketone bodies, and an increased incidence of rash. Their clin-
ical implications require currently further examination.
Q5-11 Is combination therapy with glucose-lowering agents
effective?
• In patients failing to achieve their glycemic target while on
monotherapy with a ﬁrst-line agent, consideration may be
given to increasing the dose of the ﬁrst-line agent, switching
to a more potent glucose-lowering agent, or combining the
ﬁrst-line agent with another glucose-lowering agent with a
different mechanism of action. No clear synergistic effect has
been demonstrated between agents used in combination, and
no guidelines have been established for combination therapy
with glucose-lowering agents.
• In patients with inadequate glycemic control despite
monotherapy with an SU or metformin, combination ther-
apy with another glucose-lowering agent with a different
mechanism of action is usually considered; combination
therapy with such agents has shown to be effective for low-
ering glucose levels30–36. Combination therapy with three or
more agents (other than combinations of an SU and aglin-
ide or a DPP-4 inhibitor and a GLP-1 receptor agonist)
has been shown to be effective for lowering glucose
levels37–41.
Q5-12 How should patients with inadequate glycemic control
despite treatment with glucose-lowering agents be managed?
• In patients with inadequate glycemic control despite combi-
nation therapy with glucose-lowering agents, consideration
needs to be given to reassessing MNT and/or physical activ-
ity/exercise as well as to adding basal insulin therapy or
switching to intensive insulin therapy.
6 INSULIN THERAPY
Q6-1 What types of insulin formulation are available?
• The currently available insulin formulations are classiﬁed
based on their onset/duration of action into rapid-acting
insulin, regular insulin, intermediate-acting (neutral pro-
tamine Hagedorn, NPH) insulin, long-acting insulin, pre-
mixed regular/intermediate-acting, premixed rapid-acting/
intermediate-acting (or biphasic) insulin, and rapid-acting
and long-acting insulin combination formulations.
• Intermediate- or long-acting insulin formulations are used to
supplement basal insulin secretion, while regular or rapid-
acting insulin formulations are used to supplement bolus
insulin secretion.
Q6-2 What are the indications for insulin therapy?
• Absolute indications for insulin therapy include insulin-
dependent states, including type 1 diabetes, hyperglycemic
coma (diabetic ketoacidosis, hyperglycemic hyperosmolar
syndrome, lactic acidosis), and pregnancy complicated by
diabetes that is not adequately controlled by MNT alone.
Insulin therapy is also recommended for serious infections
and surgery requiring systemic management.
• Insulin therapy is also implemented in patients with type 2
diabetes having inadequate glycemic control despite MNT,
increased physical activity/exercise and therapy with non-
insulin glucose-lowering agents or when hyperglycemia-asso-
ciated glucose toxicity must be eliminated.
Q6-3 What are the adverse reactions that occur in association
with insulin therapy?
• Insulin therapy may be associated with hypoglycemia as well
as a transient worsening of retinopathy or neuropathy in
some patients1,2. Patients receiving insulin therapy need to
be monitored for long-term risks associated with insulin
therapy, such as weight gain3.
Q6-4 What approaches are available for insulin therapy in
type 1 diabetes?
• Multiple insulin injection therapy (3–4 injections/day) or
continuous subcutaneous insulin infusion (CSII) are available
to optimize glycemic control in type 1 diabetes4.
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CQ6-5 Is intensive insulin therapy effective in suppressing
microangiopathy in type 1 diabetes?
• Intensive insulin therapy, which combines multiple insulin
injections or CSII and self-monitoring of blood glucose
(SMBG) has been shown to be effective in preventing the
onset of microangiopathy (retinopathy, nephropathy and
neuropathy) and in suppressing their progression5,6.
(Grade A: 100% agreement)
CQ6-6 Is intensive insulin therapy effective in suppressing
macroangiopathy in type 1 diabetes?
• Intensive insulin therapy that combines multiple insulin
injection therapy and SMBG has been shown to also be
effective in suppressing the progression of macroangiopathy
(coronary artery disease, cerebrovascular disease, and periph-
eral artery disease)7,8.
(Grade A: 100% agreement)
Q6-7 What are the indications/approaches for insulin therapy
in type 2 diabetes?
• Insulin therapy is to be implemented in patients with type 2
diabetes having inadequate glycemic control despite MNT,
increased physical activity/exercise and treatment with non-
insulin glucose-lowering agents3,8–10.
• While once-daily injection of long-acting insulin or twice-
daily premixed insulin (morning and evening) may be sufﬁ-
cient to provide favorable glycemic control in patients with
mild diabetes, intensive insulin therapy with multiple insulin
injection is to be implemented in those with moderate to
severe diabetes8,11,12.
• Combination therapy with insulin and oral glucose-lowering
agents (SUs13,14, fast-acting insulin secretagogues [glinides15–
17, biguanides18–21, a-glucosidase inhibitors22,23, insulin sen-
sitizers24–27, and], DPP-4 inhibitors28) or GLP-1 receptor
agonists29 are shown to improve glycemic control and
reduce the insulin dose being used in patients with type 2
diabetes.
CQ6-8 Is intensive insulin therapy effective in suppressing
microangiopathy in type 2 diabetes?
• Strict glycemic control with intensive insulin therapy has
been shown to be effective in preventing the onset of
microangiopathy (retinopathy, nephropathy, and neuropathy)
as well as in suppressing the progression of microangiopa-
thy8,9.
(Grade A: 100% agreement)
Q6-9 Is intensive insulin therapy effective in suppressing
macroangiopathy in type 2 diabetes?
• Intensive insulin therapy has been shown to be effective in
preventing the onset of macroangiopathy in type 2 dia-
betes9,30,31.
7 DIABETES SELF-MANAGEMENT EDUCATION AND
SUPPORT FOR THE SELF-MANAGEMENT OF DIABETES
CQ7-1 Are organized support and education for the self-
management of diabetes and support useful for the
management of diabetes?
• Organized education and support for the self-management
of diabetes and have been shown to be useful for diabetes
management1,2.
(Grade A: 100% agreement)
CQ7-2 Is group and individualized education useful for the
diabetes management?
• Both group and individualized education has been shown to
be useful for diabetes management3,4.
(Grade A: 85% agreement)
CQ7-3 Is the self-monitoring of blood glucose (SMBG) useful
for diabetes management?
• SMBG has been shown to be useful for patients with type 1
diabetes and for patients with type 2 diabetes receiving insu-
lin therapy5,6.
(Grade A: 95% agreement)
Q7-4 What are the psychological issues in diabetes
management and treatment?
• Diabetes is often associated with depressive symptoms and
anxiety disorders speciﬁc to the disease, leading to deﬁcient
self-care, worsening of glycemic control, an increased risk of
diabetic complications, and an impaired QOL, thus adversely
affecting the prognosis of affected patients. Intervention that
addresses both depressive symptoms and diabetes-related
mental distress and anxiety is required to improve the self-
care abilities and glycemic control of affected patients.
CQ7-5 Are psychological/behavioral approaches effective in
diabetes management?
• Psychological/behavioral approaches have been shown to be
effective in diabetes management7,8.
(Grade A: 95% agreement)
Q7-6 Is depression screening/treatment important in diabetes
management?
• After at-risk patients with diabetes are screened for depres-
sion, systematically coordinated care for both diabetes and
depression is essential9,10.
Q7-7 How are the available guidelines and practice manuals
to be used in practice?
• Practice manuals represent guides for clinicians as to how to
translate the treatment policies deﬁned in the guidelines into
daily clinical practice as they are based on systematic reviews
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of the available scientiﬁc evidence. Healthcare teams and
patients are encouraged to share relevant information and
promote decisions that would honor the needs and prefer-
ences of individual patients.
8 DIABETIC RETINOPATHY
CQ8-1 Is a routine ophthalmologic check-up useful for
preventing the onset/progression of diabetic retinopathy?
• A routine ophthalmologic check-up has been shown to be
useful for preventing the onset/progression of diabetic
retinopathy1–4.
(Grade A: 100% agreement)
CQ8-2 Is glycemic control useful for the management of
diabetic retinopathy?
• Glycemic control has been shown to be useful in suppressing
the onset/progression of diabetic retinopathy in patients with
type 1 and type 2 diabetes5–7.
(Grade A: 100% agreement)
CQ8-3 Is blood pressure control useful for the management
of diabetic retinopathy?
• Blood pressure control has been shown to be useful for sup-
pressing the onset/progression of diabetic retinopathy in
patients with type 2 diabetes8,9.
(Grade A: 100% agreement)
CQ8-4 Is lipid control useful for the management of diabetic
retinopathy?
• Fenoﬁbrates have been shown to have the potential to sup-
press the progression of diabetic retinopathy in dyslipidemia
complicated by type 2 diabetes7,10.
(Grade B: 100% agreement)
Q8-5 Are antiplatelet agents useful for preventing the onset/
progression of retinopathy?
• There is no clinical evidence to suggest the usefulness of
antiplatelet agents in suppressing the onset/progression of
diabetic retinopathy.
CQ8-6 Is ophthalmologic treatment useful for preventing the
progression of retinopathy?
• Ophthalmologic treatment such as retinal photocoagulation
has been shown to be useful for suppressing the progression
of retinopathy11,12.
(Grade A: 100% agreement)
Q8-7 Is pregnancy with pre-existing diabetes a risk factor for
the onset/progression of diabetic retinopathy?
• Pregnancy with pre-existing diabetes has been shown to pro-
mote the onset/progression of diabetic retinopathy13–15.
Q8-8 Is diabetic retinopathy a risk factor for the onset of
other diabetes-associated complications?
• Diabetic retinopathy is a risk factor for diabetic nephropathy
and macroangiopathy16–20.
9 DIABETIC NEPHROPATHY
CQ9-1 Is the measurement of urinary albumin useful for the
early diagnosis of diabetic nephropathy?
• The measurement of urinary albumin has been shown to be
useful in the early diagnosis of diabetic nephropathy1.
(Grade A: 100% agreement)
Q9-2 What parameters are used to assess the renal function?
• The renal function is to be evaluated as the estimated
glomerular ﬁltration rate (eGFR) from the serum creatinine
(Scr) concentration, as determined by an enzymatic
method2.
• Insulin clearance (Ic) or creatinine clearance (Ccr) allows
the renal function to be more accurately assessed than the
eGFR.
• Estimated glomerular ﬁltration rate (eGFR)
1. The eGFR is easily assessed as an index of the renal func-
tion, rather than Ccr or insulin clearance (Cin). The eGFR
is calculated by the following equation for Japanese adults
based on the Scr concentration2:
eGFRðmL=min=1:73m2Þ ¼ 194 Scrðmg/dLÞ  1:094
 Age0:287ð0:789; if femaleÞ:
The accuracy rate of this equation (within 30% of the mea-
sured GFR) is 75%. The eGRF may be overestimated in sub-
jects with reduced muscle mass.
2. Alternatively, the eGFR can be calculated by the following
equation based on the serum cystatin C (Cys-C) concentra-
tion20:
eGFRcys-c (mL/min=1:73m2Þ ¼ 104 Cys-C 1:019
 0:996Ageð0:996; if femaleÞ
 8:
The serum Cys-C concentration is inﬂuenced by muscle mass
or diet (or nutritional conditions).
CQ9-3 Is glycemic control effective for the management of
diabetic nephropathy?
• Glycemic control has been shown to be effective for sup-
pressing the progression of nephropathy in patients with
early-stage diabetic nephropathy4,5.
(Grade A: 90% agreement)
• Glycemic control has been shown to have the potential to
suppress the progression of nephropathy in patients with
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overt diabetic nephropathy6.
(Grade B: 90% agreement)
CQ9-4 Is blood pressure control effective for the management
of diabetic nephropathy?
• Blood pressure control has been shown to be effective for
the management of diabetic nephropathy in all stages7–9.
(Grade A: 95% agreement)
CQ9-5 Is lipid control effective for the management of
diabetic nephropathy?
• Lipid control has been shown to be effective for suppressing
the progression of diabetic nephropathy in patients without
renal impairment10,11.
(Grade B: 95% agreement)
CQ9-6 Are angiotensin-converting enzyme (ACE) inhibitors
and angiotensin II receptor antagonists (ARBs) recommended
as ﬁrst-line medications for blood pressure control in patients
with diabetic nephropathy?
• Angiotensin-converting enzyme (ACE) inhibitors and angio-
tensin II receptor antagonists (ARB) are recommended as
ﬁrst-line medications for blood pressure control in patients
with diabetic nephropathy12,13.
(Grade A: 100% agreement)
CQ9-7 Is dietary salt restriction recommended for the
management of diabetic nephropathy?
• Dietary salt restriction is recommended for the management
of diabetic nephropathy14,15.
(Grade A: 95% agreement)
Q9-8 Is dietary protein restriction effective for the
management of diabetic nephropathy?
• Dietary protein restriction may potentially be effective for
the management of diabetic nephropathy16,17.
Q9-9 Is the treatment of anemia effective for suppressing the
progression of diabetic nephropathy?
• It remains unclear if the treatment of anemia may have a
role in suppressing the progression of diabetic nephropa-
thy18.
Q9-10 Is diabetic nephropathy a risk factor for other
complications in diabetic patients?
• Diabetic nephropathy frequently occurs concomitantly with
cardiovascular disease.
• Patients with diabetic nephropathy show a high rate of car-
diovascular disease-related mortality.
• A decreased GFR and the occurrence of albuminuria are
independent risk factors for cardiovascular disease19.
10 DIABETIC NEUROPATHY
Q10-1 How is diabetic neuropathy diagnosed? (Table 4)
• Diabetic neuropathy represents one of the most common
complications in patients with diabetes. It is therefore prefer-
able that patients with diabetes undergoing physical exami-
nations be examined for the presence or absence of diabetic
neuropathy; if present, its clinical stage determined.
• In diagnosing diabetic neuropathy, patients are to be not only
interviewed about neurological symptoms but also to be
examined for sensations such as pain sensation (with a tooth-
pick/bamboo skewer), vibration sensation (with a C128 tun-
ing fork), pressure sensation (with a monoﬁlament) as well as
for Achilles’ tendon reﬂex; the assessment can be as compre-
hensive as possible. Other ﬁndings, such as dry feet, cracked
feet, foot calluses or ulcers, may suggest the presence of neu-
ropathy and prove helpful in establishing the diagnosis.
• Heart rate variability (HRV) testing is a convenient and use-
ful test to assess the autonomic nerve function.
• Nerve conduction examinations are essential for the deﬁni-
tive diagnosis of diabetic neuropathy and are useful in the
diagnosis of asymptomatic neuropathy.
Q10-2 How is diabetic neuropathy classiﬁed?
• Diabetic neuropathy is divided into distal symmetric
polyneuropathy and focal mononeuropathy1,2.
Q10-3 What are the risk factors for the onset/progression of
diabetic neuropathy?
• The risk factors for the onset/progression of diabetic neu-
ropathy include: ① poor glycemic control, ② duration of
diabetes, ③ hypertension, ④ dyslipidemia, ⑤ smoking, and
⑥ drinking3. Among these, poor glycemic control is the
Table 4 | The diagnostic criteria for distal symmetric polyneuropathy
proposed by the Diabetic Neuropathy Study Group, Japan (the original
version was published in 2004; the revised version was published in
2005)
Prerequisite condition (Must meet the following two items)
1. Diagnosed as diabetes
2. Other neuropathies than diabetic neuropathy can be excluded
Criteria (Meet any two of following three items)
1. Presence of symptoms considered to be due to diabetic
polyneuropathy
2. Decrease or disappearance of bilateral ankle reflex
3. Decreased vibration in bilateral medial malleoli
Diabetic neuropathy has no specific symptoms or assessments and no
global consensus has been reached on its diagnostic criteria. Thus,
while a comprehensive assessment is required to establish its diagnosis
based on neurological symptoms and laboratory test results, the validity
of the criteria proposed by the Japanese Study Group of Diabetic
Nephropathy12,13 is thought to be high enough for routine clinical use.
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most prominent risk factor; indeed, the incidence of neu-
ropathy in patients with poor glycemic control has been
shown to be high.
CQ10-4 Is glycemic control effective for the management of
diabetic neuropathy?
• Strict glycemic control has been shown to suppress the
onset/progression of diabetic neuropathy4,5.
(Grade A: 95% agreement)
Q10-5 How is pharmacotherapy to be implemented in
patients with neurosensory damage?
• Neurosensory damage often resolves with improved glycemic
control and lifestyle modiﬁcation in patients with mild painful
neuropathy. Non-steroidal anti-inﬂammatory drugs (NSAIDs)
have only been shown to be effective in mild cases.
• Tricyclic antidepressants6, pregabalin7,8, and duloxetine9,10
are recommended as ﬁrst-line medications for patients with
moderate to severe painful neuropathy.
• Epalrestat has been shown to suppress the progression of
diabetic neuropathy in some patients.
Q10-6 How is autonomic nerve damage treated?
• Neurosensory damage often improves with improved glyce-
mic control and lifestyle modiﬁcation in patients with mild
autonomic neuropathy. However, symptom-speciﬁc pharma-
cotherapy is required for patients whose activities of daily liv-
ing (ADL) are impaired in association with advanced
neuropathy.
Q10-7 How is mononeuropathy treated ?
• Mononeuropathy has been shown to often resolve sponta-
neously, independent of glycemic control.
Q10-8 Is diabetic neuropathy a risk factor for other
complications in diabetic patients?
• Diabetic neuropathy has been shown to be a risk factor for
diabetic retinopathy and nephropathy11.
11 DIABETIC FOOT
Q11-1 What is diabetic foot?
• Diabetic foot is globally deﬁned as ‘infections, ulcers and
destructive lesions occurring on the lower limb tissue of
patients with diabetes in association with ongoing neuropa-
thy and peripheral artery disease’.
• Diabetic foot occurs in response to external factors in the
presence of hypoesthesia due to neuropathy, foot deformities,
dry or keratinized skin, and decreased blood ﬂow due to
peripheral artery disease. When diabetic foot is complicated
by infection, it is likely to become severe, leading not only to
lower limb amputation but also to a worse prognosis1,2.
CQ11-2 Is a routine foot examination effective for the
prevention of diabetic foot?
• While there is a paucity of evidence to support the effective-
ness of routine foot examinations in the prevention of dia-
betic foot, the incidence of lower limb amputations has been
observed to decrease following the introduction of foot care,
including foot examinations, in clinical practice3. Foot exami-
nations are essential for the early detection of diabetic foot
and the implementation of foot care and are thus thought to
be effective for the prevention of diabetic foot.
(Grade A: 85% agreement)
CQ11-3 Is foot care education effective for the prevention of
diabetic foot?
• Foot care education is thought to promote the acquisition of
relevant knowledge and improve self-care activities and is
thus thought likely to be effective for achieving the long-term
prevention of diabetic foot1,4.
(Grade A: 90% agreement)
CQ11-4 Is glycemic control effective for preventing diabetic
foot or lower limb amputations?
• To date, very few studies have investigated the effects of
intervention with regard to glycemic control on diabetic foot
or amputations5; however, glycemic control is recommended
for the prevention of neuropathy and macroangiopathy,
which are risk factors for diabetic foot.
(Grade B by consensus: 100% agreement)
CQ11-5 Is foot care effective for the prevention of foot ulcers
or limb salvage in high-risk patients?
• While very few studies have shown direct evidence to sup-
port the effectiveness of foot care in the prevention of foot
ulcers or lower limb amputations in high-risk patients, multi-
disciplinary collaboration on foot care has been shown to
reduce the incidence of major amputations6.
(Grade A: 100% agreement)
Q11-6 How are foot ulcers treated?
• The treatment of diabetic foot in patients with diabetes
entails a wide array of interventions, which include control
of their general condition, local procedures (i.e., debride-
ment), the treatment of infectious disease, revascularization
for severe lower limb ischemia, the use of non-weight-bear-
ing/off-loading devices and specially prepared shoes, walking
rehabilitation, nutritional education, and care support, in
which multidisciplinary team-based care involving diverse
specialists and practitioners remains the cornerstone1.
• Infections, abscesses or necrotizing fasciitis associated with
the presence of gas in the deep tissues are indications for
emergency surgery. While no established criteria are available
with regard to for indications for amputation, the blood ﬂow
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of the prospective amputation site must be evaluated prior
to amputation7,8.
CQ11-7 Is team-based care effective in preventing diabetic
foot and treating foot ulcers?
• Multidisciplinary team-based care is reported to improve the
outcomes of foot ulcer treatment9. While there is no direct
evidence to show that multidisciplinary team-based care pre-
vents diabetic foot ulcers, the incidence of foot amputations
has decreased over time since the establishment of multidis-
ciplinary team-based care, suggesting that multidisciplinary
team-based care is effective in preventing foot lesions10.
(Grade A: 100% agreement)
CQ11-8 Is foot ulcer treatment effective in maintaining the
quality of life (QOL) of affected patients?
• Foot ulcer treatment has been shown to be effective in main-
taining the QOL of affected patients11,12.
(Grade A: 100% agreement)
Q11-9 Is diabetic foot a risk factor for other complications in
patients with diabetes?
• Diabetic foot is signiﬁcantly associated with the onset of car-
diovascular disease, higher overall mortality and the onset of
depression, suggesting that diabetic foot represents a risk
factor for mortality, cardiovascular disease and depres-
sion13,14.
12 DIABETIC MACROANGIOPATHY
Q12-1 When and how is risk management to be initiated for
the prevention of diabetic macroangiopathy?
• It is recommended that the established risk factors for dia-
betic macroangiopathy (i.e., impaired glucose tolerance
[IGT], hypertension, dyslipidemia, obesity, and chronic kid-
ney disease [CKD]), be detected and managed at an early
stage1.
Q12-2 In which diabetic patients is risk management likely to
be beneﬁcial in preventing diabetic macroangiopathy?
• All patients with diabetes may be deemed candidates for risk
management. However, tight pharmacological blood pressure
and glucose control may be adversely associated with an
increased risk of events in older patients or those with
advanced vascular complications2.
CQ12-3 Are the modiﬁcation of lifestyle habits and the
correction of obesity effective in preventing diabetic
macroangiopathy?
• Conditions, such as IGT, hypertension, dyslipidemia, obesity,
and CKD, and lifestyle habits, such as physical inactivity, an
excessive salt intake, and smoking, all represent risk factors for
cardiovascular events. The modiﬁcation of lifestyle habits and
the correction of obesity are recommended, given that they are
shown to be associated with the amelioration of these risk fac-
tors3.
(Grade A: 95% agreement)
CQ12-4 Is glycemic control effective against diabetic
macroangiopathy?
• Tight glycemic control, initiated early after the onset of dia-
betes, has been shown to be effective in suppressing the risk
of diabetic macroangiopathy4.
(Grade A: 100% agreement)
CQ12-5 Is blood pressure control effective in preventing
diabetic macroangiopathy?
• Tight blood pressure control has been shown to be effective
in suppressing the risk of diabetic macroangiopathy5.
(Grade A: 100% agreement)
CQ12-6 Is lipid control effective in preventing diabetic
macroangiopathy?
• Lipid control has been shown to be effective in the primary
and secondary prevention of diabetic macroangiopathy6,7.
(Grade A: 100% agreement)
CQ12-7 Are antiplatelet agents effective in preventing diabetic
macroangiopathy?
• The use of antiplatelet agents has been shown to be effective
in the secondary prevention of diabetic macroangiopathy8.
(Grade A: 100% agreement)
• The use of antiplatelet agents is not recommended for the
primary prevention of diabetic macroangiopathy in patients
with diabetes9.
(Grade A: 90% agreement)
Q12-8 Is diabetic macroangiopathy a risk factor for other
complications in diabetic patients?
• Hyperglycemia represents a common risk factor for diabetic
retinopathy, nephropathy, neuropathy, and macroangiopathy,
thus suggesting a relationship between these conditions.
However, at present, there is no clear evidence to demon-
strate any direct relationship.
13 DIABETES AND PERIODONTITIS
Q13-1 What is periodontal disease?
• Periodontal disease is an inﬂammatory disease involving pla-
que bacteria and is broadly classiﬁed into gingivitis, in which
inﬂammation is conﬁned to the gingiva, and periodontitis,
which involves a loss of supporting tissue.
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• Periodontal disease is a disease of the oral cavity that is
reported to affect approximately 80% of the Japanese individ-
uals of middle age or older and is the foremost cause of den-
tal extraction.
• The treatment of periodontal disease entails not only estab-
lishing plaque control in affected patients but also improving
inﬂammation through plaque and calculus removal from
periodontal pockets and ensuring routine post-removal peri-
odontal maintenance care aimed at preventing a relapse of
the disease.
Q13-2 Does diabetes inﬂuence the onset/progression of
periodontal disease?
• Periodontal disease has been shown to occur more frequently
among patients with type 1 diabetes in comparison to young
healthy individuals1.
• The risk of the onset of periodontal disease and the progres-
sion of alveolar bone resorption is signiﬁcantly increased in
patients with type 2 diabetes and an HbA1c value of ≥6.5%2.
CQ13-3 Is diabetes treatment effective in improving
periodontal disease?
• Diabetes treatment may lead to the improvement of peri-
odontal tissue inﬂammation3.
(Grade B: 100% agreement)
Q13-4 Does periodontal disease affect glycemic control?
• Periodontal disease as an inﬂammatory disease has been epi-
demiologically shown to adversely affect glycemic control4.
• As periodontal disease becomes more severe, it becomes
more difﬁcult to achieve glycemic control in affected
patients5.
CQ13-5 Is treating periodontal disease effective in improving
glycemic control?
• The treatment of periodontal disease has been shown to lead
to improvement in the glycemic status of some patients with
type 2 diabetes6.
(Grade B: 95% agreement)
14 DIABETES COMPLICATED BY OBESITY (INCLUDING
METABOLIC SYNDROME)
Q14-1 What are the causes of obesity?
• Obesity is classiﬁed into secondary obesity (i.e., obesity with
clear underlying causes), and primary obesity (i.e., obesity
with no clear causes but which is associated with lifestyle
habits such as physical inactivity)1.
• While primary obesity is most frequent of all forms of obe-
sity, secondary obesity includes endocrinologically-induced
obesity, inherited obesity, hypothalamic obesity and drug
induced obesity1.
Q14-2 How is obesity diagnosed?
• In Japan, obesity is deﬁned by a body mass index (BMI) of
≥25 kg/m2 or higher according to the Japan Society for the
Study of Obesity; however, obesity should not to be handled
as a disease in patients without health problems1.
• Obesity should be handled as a disease in patients with
obesity-induced or obesity-associated health problems, or in
patients who are likely to have obesity-associated health
problems and for whom weight loss is medically indi-
cated1.
• Obesity as a disease includes ① obesity-induced or obesity-
associated conditions requiring weight reduction for health
problems (that are likely to be improved or prevented with a
certain level of weight loss); and ② visceral fat-associated
obesity (visceral fat area ≥100 cm2 at the umbilical level
measured by CT in patients who are currently free of, but
who are likely to develop health problems such as diabetes
(deﬁned as high-risk obesity requiring intervention with life-
style modiﬁcation)1.
Q14-3 How is obesity-associated diabetes to be managed?
• Secondary obesity is to be carefully ruled out in patients with
type 2 diabetes and obesity, and those who are thought to
be likely to have primary obesity are to be interviewed about
their living environmental and psychological factors. Atten-
tion is to be paid to the discontinuation or modiﬁcation of
any lifestyle habits that cause obesity2. This is to entail, ﬁrst,
instructing patients on lifestyle modiﬁcation including MNT
and/or physical activity/exercise, stress management and a
regular lifestyle to lose weight2. Pharmacotherapy is to be
considered for patients whose glycemic control is inadequate
despite maintaining lifestyle modiﬁcations over a certain per-
iod2.
• Left untreated, obesity often becomes more severe in dia-
betic patients and obese patients receiving therapy for
hyperglycemia alone3. Attention needs to be focused on
ensuring that these patients proactively modify their life-
styles to achieve favorable glycemic control without weight
gain3.
Q14-4 Is behavioral therapy effective in reducing body weight
and achieving glycemic control in patients with type 2
diabetes and obesity?
• Behavioral therapy needs to be combined with lifestyle
modiﬁcation in order to achieve and maintain weight
reduction over the long term in patients with type 2 dia-
betes and obesity4. Obesity is associated with abnormal eat-
ing behavior such as speed eating characterized, by an
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excessive intake of energy over a short time, and impulse
eating, and eating between meals from post-lunch to night-
time can be problematic in many of these patients. Thus,
when their treatment goals have been determined, these
patients must be monitored and their overeating behavior
should be evaluated through diet journals and body weight
measurements to establish improvements in their eating
behavior. Behavioral enhancement, such as through the
implementation of routine motivation measures, is thought
to be effective in maintaining desired behavioral changes.
However, there is currently no clear evidence to support
the effectiveness of behavioral therapy in the achievement
of glycemic control in patients with type 2 diabetes and
obesity.
Q14-5 Is pharmacotherapy effective for achieving glycemic
control in patients with type 2 diabetes and obesity?
• The use of insulin or SUs is to be minimized in patients
with type 2 diabetes and obesity, given that their uncritical
use may promote obesity3.
• Medications associated with weight gain include (in addition
to insulin and SUs) rapid-acting insulin secretagogues (glin-
ides), thiazolidinediones (TZDs), tricyclic antidepressants
(amitriptyline), and atypical antipsychotic agents (olanzap-
ine). The use of these drugs by patients with type 2 diabetes
and obesity warrants caution3.
• The appetite-inhibitory and weight-reducing properties of
glucagon-like peptide 1 (GLP-1) receptor agonists may
improve glycemic control in patients with type 2 diabetes
and obesity3. Indeed, some GLP-1 receptor agonists are cur-
rently being used to treat obesity overseas.
CQ14-6 Is surgical therapy effective for patients with type 2
diabetes and high-degree obesity?
• The role of obesity surgery has drawn attention. Obesity sur-
gery includes not only bariatric surgery for high-degree obe-
sity, but also metabolic surgery, which improves diabetes or
prevents the onset/progression of the disease. Thus, obesity
surgery is an effective treatment option for patients with type
2 diabetes and obesity who are less amenable to weight
reduction5.
(Grade B: 100% agreement)
Q14-7 What is metabolic syndrome?
• Metabolic syndrome is deﬁned as a condition that involves
any two of the following conditions, in addition to visceral
fat accumulation (visceral fat area ≥100 m2 on CT measure-
ment at the level of the umbilicus): fasting hyperglycemia
(≥110 mg/dL (6.1 mmol/L), dyslipidemia such as hyper-
triglyceridemia (≥150 mg/dL), hypo-high-density-lipoprotein
(HDL)-cholesterolemia (<40 mg/dL), and high blood pres-
sure (≥130/85 mmHg)6.
15 HYPERTENSION ASSOCIATED WITH DIABETES
Q15-1 Is hypertension a risk factor for macroangiopathy in
patients with diabetes?
• Both diabetes and hypertension are established risk factors
for atherosclerosis-associated macroangiopathy; furthermore,
patients with diabetes and hypertension have a higher inci-
dence of macroangiopathy and a poorer prognosis1.
Q15-2 Is hypertension a risk factor for microangiopathy in
patients with diabetes?
• Hypertension in patients with diabetes represents a risk fac-
tor for microangiopathy, such as diabetic nephropathy,
retinopathy and neuropathy2.
• The correction of hypertension potentially prevents the pro-
gression of diabetic nephropathy in patients with diabetes3.
• Angiotensin II receptor antagonists (ARBs) and angiotensin-
converting enzyme (ACE) inhibitors potentially prevent the
progression of microangiopathy3,4.
Q15-3 What is the ofﬁce blood pressure threshold for
initiating antihypertensive therapy in patients with diabetes?
(Figure 6)
• The initiation antihypertensive therapy is deemed to be
appropriate for patients with an ofﬁce blood pressure of
≥130/80 mmHg.
• Intervention with antihypertensive agents are to be immedi-
ately initiated for patients with an ofﬁce blood pressure of
≥140/90 mmHg.
• Lifestyle modiﬁcation (lasting no more than 3 months) may
be indicated for patients with diabetes and an ofﬁce blood
pressure of 130–139/80–89 mmHg if such modiﬁcation is
expected to achieve the patient’s blood pressure goal; how-
ever, antihypertensive agents are to be initiated immediately
when such modiﬁcation is considered to be unlikely to
achieve the blood pressure goal.
• Home blood pressure measurement is strongly recom-
mended and home blood pressure measurement should be
performed prior to ofﬁce blood pressure measurement when
there is discrepancy between the home and ofﬁce blood pres-
sure readings.
• A home blood pressure of ≥125/75 mmHg is deemed to be
an appropriate level for initiating intervention in patients
with diabetes.
(Consensus between the Japanese Society of Hypertension
and the Japan Diabetes Society)
CQ15-4 Is controlling ofﬁce blood pressure to <130/80 mmHg
effective in preventing the onset of complications in patients
with diabetes and hypertension?
• A blood pressure of <130/80 mmHg deemed to be appropri-
ate as the ofﬁce blood pressure goal for preventing complica-
tions in patients with diabetes and hypertension5,6.
(Grade B: 90% agreement)
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• While controlling blood pressure to the blood pressure goal
is effective in preventing diabetic complications, particularly
cerebrovascular disease, sufﬁcient attention should be paid to
the potential for organ hypoperfusion in association with
decreased blood pressure in patients with diabetes and
atherosclerotic coronary disease or peripheral artery disease,
or in older patients with diabetes7,8.
(Grade B: 100% agreement)
(Consensus between the Japanese Society of Hypertension
and the Japan Diabetes Society)
CQ15-5 Are angiotensin-converting enzyme (ACE) inhibitors or
angiotensin II receptor antagonists (ARBs) used as ﬁrst-line
antihypertensive medications for patients with diabetes and
hypertension?
• ACE inhibitors or ARBs are to be used as ﬁrst-line antihy-
pertensive drugs in patients with diabetes and hypertension,
given their organ-protective and insulin-sensitizing proper-
ties9,10.
(Grade A: 100% agreement)
(Consensus between the Japanese Society of Hypertension
and the Japan Diabetes Society)
Q15-6 Which is preferable, a calcium channel blocker (CCB) or
a diuretic, as an add-on agent in patients with diabetes and
hypertension
• A calcium channel blocker or a low-dose thiazide diuretic
is to be added or combination therapy with three agents
is to be implemented when treating diabetic patients whose
blood pressure is less well controlled with an ACE inhibi-
tor/ARB.
(Consensus between the Japanese Society of Hypertension
and the Japan Diabetes Society)
16 DYSLIPIDEMIA ASSOCIATED WITH DIABETES
Q16-1 Is dyslipidemia a risk factor for macroangiopathy in
diabetes?
• Dyslipidemia is a risk factor for macroangiopathy1.
• Hyper-low-density-lipoprotein (LDL)-cholesterolemia is a
strong risk factor for coronary artery disease2.
Q16-2 Is dyslipidemia a risk factor for microangiopathy in
diabetes?
• Hypertriglyceridemia is a risk factor for microangiopathy3.
Blood pressure on initiation of treatment entry : ≥130/80 mmHg
Blood pressure target < 130/80 mmHg*
Start antihypertensive treatment simultaneously with lifestyle modiﬁcation/glycemic control.
1)  Those with blood pressure 140/90 mmHg: Start antihypertensive drug therapy.
2)  Those with blood pressure 130–139/80–89 mmHg: In those in whom lifestyle modiﬁcation is
     thought to be likely to result in decreased blood pressure, lifestyle modiﬁcation may be 
     attempted for up to 3 months. If their blood pressure value after modiﬁcation is 130/80 mmHg,
     they should be clinically diagnosed as having hypertension and antihypertensive therapy
     should be initiated.
Improvement on lifestyle, blood glucose management together with pharmaceutical treatment*
Combined use of 3 drugs: ARB or ACE inhibitors, Ca antagonist, diuretic
Increase drug dose Combination of an Ca antagonist and a diuretic
Inadequate eﬀectivenes
Inadequate eﬀectivenes
Figure 6 | The treatment of hypertension complicating diabetes mellitus. Excerpt from: The Japanese Society of Hypertension, Guidelines for the
Treatment of Hypertension, 2014, p. 78. *Care needs to be taken to closely monitor patients with coronary atherosclerosis, peripheral arterial
disease, or older patients with diabetes, for decreased organ blood flow. [Colour figure can be viewed at wileyonlinelibrary.com]
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• Hypo-high-density-lipoprotein (HDL)-cholesterolemia is a
risk factor for microangiopathy4.
Q16-3 What are the threshold for initiating antidyslipidemic
therapy and its control goals in diabetes? (Table 5)
• The primary goal of antidyslipidemic therapy is to control
the LDL-cholesterol level to: <100 mg/dL in patients with a
history of coronary artery disease and to <120 mg/dL in
patients without a history of coronary artery disease.
• The control goal for fasting triglyceride (TG) is <150 mg/dL.
• The control goal for HDL-cholesterol is ≥40 mg/dL.
CQ16-4 Is MNT effective against dyslipidemia in patients with
diabetes?
• MNT has been shown to be effective against dyslipidemia in
patients with diabetes5.
(Grade A: 100% agreement)
• The intake of polyunsaturated fatty acids (PUFA) is recom-
mended6.
(Grade A: 100% agreement)
CQ16-5 Is physical activity/exercise effective against
dyslipidemia in patients with diabetes?
• Physical activity/exercise has been shown to be effective
against dyslipidemia in patients with diabetes7.
(Grade A: 100% agreement)
CQ16-6 Is statin therapy effective in reducing the risk of
cardiovascular disease (CVD) or mortality in patients with
diabetes and dyslipidemia?
• The use of statins has been shown to reduce the risk of CVD
and mortality in patients with diabetes and dyslipidemia8.
(Level of recommendation: A [100% consensus])
• Statins are the drugs of choice for hyper-LDL-cholesterole-
mia in patients with diabetes9.
(Grade A: 100% agreement)
CQ16-7 Is the use of non-statin drugs effective in reducing
the risk of CVD or mortality in patients with diabetes and
dyslipidemia?
• The use of ﬁbrates has been shown to reduce the risk of
non-fatal CVD in patients with diabetes and dyslipidemia10.
(Grade B: 100% agreement)
• The use of ﬁbrates is to be considered for patients with dia-
betes and hypertriglyceridemia11.
(Grade B: 100% agreement)
17 IMPAIRED GLUCOSE METABOLISM IN PREGNANCY
CQ17-1 Does glycemic control before and during pregnancy
lead to improvements in the maternal and neonatal
prognosis?
• While poor glycemic control before and during early-phase
pregnancy has been shown to be associated with an
increased incidence of congenital anomalies and fetal death,
strict glycemic control from well before pregnancy has been
shown to be associated with a reduced incidence of these
complications1.
(Grade A: 95% agreement)
• While poor glycemic control during pregnancy has been
shown to be associated with an increased risk of perinatal
complications, including fetal macrosomia, strict glycemic
control during pregnancy has been shown to be associated
with a reduction in the risk of these complications2.
(Grade A: 100% agreement)
Q17-2 How are hyperglycemic disorders diagnosed in
pregnancy? (Table 6)
• Hyperglycemic disorders in pregnancy include ① gestational
diabetes mellitus (GDM), ② overt diabetes in pregnancy,
and ③ pre-gestational diabetes mellitus, and are diagnosed
based on 75 g oral glucose tolerance tests (OGTTs), HbA1c
values and the clinical ﬁndings3.
Q17-3 How should patients with diabetes be managed and
treated before pregnancy?
• Patients with diabetes who wish to become pregnant are to
be fully informed about the importance of strict glycemic
control being implemented from well before pregnancy to
prevent congenital anomalies, fetal death and miscarriage
due to poor glycemic control1.
• Every effort should be made to achieve glycemic control that
is as close to normal as possible while at the same time
avoiding hypoglycemia in these patients1.
• Given that oral glucose-lowering agents are not recom-
mended in patients who wish to become pregnant, insulin
therapy is to be implemented if glycemic control is deemed
inadequate despite MNT1.
• All patients with diabetes who wish to become pregnant are
to be evaluated for diabetic complications. If complications
are present, they should be managed from well before preg-
nancy, as they have been shown to adversely affect the
maternal prognosis and pregnancy outcomes4.
• Careful family planning is to be recommended for patients
who wish to become pregnant and the patient is to be fully
informed about the potential need for contraception, to
Table 5 | The lipid control target values in patients with diabetes
Coronary artery disease Lipid control target values (mg/dL)
LDL-C HDL-C TG Non-HDL-C
Present <120 ≥40 <150 <150
Absent <100 <130
Edited by Japan Atherosclerosis Society: Guidelines for Prevention of
Atherosclerotic Cardiovascular Diseases, published 2012,P.42.
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avoid congenital anomalies and miscarriage and in order to
ensure healthy neonatal development and a favorable long-
term maternal prognosis1.
• All patients with diabetes who wish to become pregnant are
to be evaluated for their use of antihypertensive and lipid-
lowering agents; these agents are to be reconsidered in view
of pregnancy.
Q17-4 How should diabetic retinopathy be managed and
treated before and during pregnancy?
• Diabetic retinopathy has been shown to worsen during preg-
nancy and after delivery. Thus, those who wish to become
pregnant should be evaluated for glycemic control and dia-
betic retinopathy. If present, diabetic retinopathy is to be
managed from well before pregnancy. Given that pre-prolif-
erative/proliferative retinopathy is more likely to worsen,
patients with either form of retinopathy are to be instructed
to attempt to conceive only after their disease has become
stable with ophthalmologic treatment5.
Q17-5 How should diabetic nephropathy be managed and
treated before and during pregnancy?
• Diabetic nephropathy during pregnancy has been shown to
lead not only to the onset of pregnancy-induced hyperten-
sion, premature delivery, and renal dysfunction in mothers,
but also to growth retardation in their infants. Thus, the
condition represents a high risk for both the mother and
baby4.
• When a patient indicates a wish to become pregnant, their
renal function is to be evaluated based on urinary albumin/
protein, the glomerular ﬁltration rate (GFR), and creatinine
clearance (Ccr), from well before pregnancy6.
• Given that pregnancy has been shown to be associated with
a further worsening of the renal function—likely leading to
poor perinatal prognosis in patients with renal impairment
—patients with renal impairment are to be fully informed
about these risks before pregnancy and those who become
pregnant are to be given careful counselling as to whether to
continue pregnancy6.
Q17-6 How pregnant women are screened for gestational
diabetes mellitus (GDM)?
• Given that screening for gestational diabetes mellitus
(GDM), based on risk factors, such as a family history of
diabetes, obesity, a history of fetal macrosomia and age, is
thought likely to lead to many patients with GDM being
missed, it is preferable that all pregnant women be consis-
tently screened for GDM, based on a glucose-based assess-
ment including casual and fasting glucose measurements and
a glucose challenge test (GCT); ideally, at ﬁrst consultation
and at between 24 and 28 weeks of gestation7.
Q17-7 How should glycemic control be implemented in cases
involving hyperglycemic disorders during pregnancy
• Glycemic control in pregnant women with hyperglycemic
disorders is intended to control their glucose to as close to
Table 6 | Gestational diabetes mellitus: Its definition and diagnostic criteria
Definition Gestational diabetes mellitus is defined as a state of pre-diabetic impaired glucose tolerance which is identified or which
occurs for the first time during pregnancy and which does not include overt diabetes in pregnancy or pregnancy




Individuals are to be diagnosed with gestational diabetes mellitus if they meet any of the following criteria in a 75 g
oral glucose tolerance test (OGTT):
① Fasting glucose value: ≥92 mg/dL (5.1 mmol/L)
② 1-h post-OGTT glucose value: ≥180 mg/dL (10.0 mmol/L)
③ 2-h post-OGTT glucose value: ≥153 mg/dL (8.5 mmol/L)
Overt diabetes in
pregnancy*
Individuals are to be diagnosed with overt diabetes in pregnancy if they meet either of the following during pregnancy:
① Fasting glucose: ≥126 mg/dL (7.0 mmol/L)
② HbA1c: ≥6.5%
* Individuals with casual glucose values of ≥200 mg/dL (11.1 mmol/L) or 2-h post-75 g OGTT glucose values
of ≥200 mg/dL (11.1 mmol/L) in pregnancy are to be examined to see if they meet either ① or② with the
potential diagnosis of overt diabetes in pregnancy in mind.†
Pre-gestational
diabetes mellitus
Individuals are to be diagnosed with pre-gestational diabetes mellitus if they meet either of the following:
① Diabetes mellitus diagnosed before pregnancy
② Pregnancy associated with unequivocal evidence of diabetic retinopathy
*Overt diabetes mellitus in pregnancy includes diabetes mellitus overlooked before pregnancy, impaired glucose tolerance resulting from changes
in glucose metabolism during pregnancy and type 1 diabetes mellitus occurring during pregnancy. In either case, the diagnosis needs to be con-
firmed in affected individuals after delivery. †Individuals are expected to show higher post-OGTT glucose values during pregnancy than usual,
reflecting increased physiological insulin resistance during pregnancy, particularly in later stage. Thus, the casual glucose and post-75 g OGTT values
defined in the diagnostic criteria for diabetes mellitus during non-pregnancy are not readily applicable (adapted from11).
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that of a healthy pregnant woman as possible, while mini-
mizing the incidence of hypoglycemia; the target fasting glu-
cose level is 70–100 mg/dL (3.9–5.6 mmol/L) and the target
postprandial 2-h level is <120 mg/dL (6.7 mmol/L).
• MNT in pregnant women with hyperglycemic disorders
involves not only providing necessary and sufﬁcient nutrition
for healthy fetal development but also ensuring strict glyce-
mic control and appropriate weight gain8.
• Insulin therapy is to be implemented if patient’s glycemic con-
trol goal is not achievable with MNT. Intensive insulin ther-
apy, which involves self-monitoring of blood glucose (SMBG),
is to be employed to better ensure sustained glycemic control9.
• While there is a paucity of evidence to support the usefulness
of increased physical activity/exercise in the management of
hyperglycemic disorders in pregnancy, increased physical
activity/exercise may have a role to play in promoting health
including improving maternal glycemic control, suppressing
excessive weight gain, and providing a change of pace.
Q17-8 How should delivery be managed in pregnant women
with impaired glucose metabolism?
• While vaginal delivery represents the standard approach in
women with hyperglycemic disorders as in healthy preg-
nancy, the approach should be individualized, with consider-
ation given to fetal growth and well-being.
• Given that maternal hyperglycemia is a risk factor for neona-
tal hypoglycemia, the maternal glucose level at delivery is to
be maintained at ≤100 mg/dL (5.6 mmol/L) in pregnant
patients with hyperglycemic disorders.
Q17-9 How should patients with gestational diabetes mellitus
(GDM) or overt diabetes during pregnancy be evaluated and
managed after delivery?
• Patients with gestational diabetes mellitus (GDM), who are at
high risk of developing impaired glucose tolerance (IGT) after
delivery10, need to be evaluated for glucose metabolism from
early in the post-partum period with a 75 g OGTT performed
at between 6 and 12 weeks post-delivery. Thereafter, they
should be followed up on a routine basis, but instructed on
MNT and increased physical activity/exercise as required.
18 PEDIATRIC/ADOLESCENT DIABETES
Q18-1 What is the basic treatment policy for pediatric/
adolescent diabetes?
• The treatment policy for pediatric/adolescent patients with
diabetes is to accommodate age-speciﬁc differences in devel-
opment/growth and comprehension, with sufﬁcient consider-
ation given to the patient’s mental immaturity1,2.
Q18-2 How is pediatric/adolescent type 1 diabetes diagnosed?
• The diagnosis of pediatric/adolescent type 1 diabetes consists
of demonstrating evidence of progressively declining
endogenous insulin secretion or its depletion; islet-speciﬁc
autoantibodies have been shown to be present in the major-
ity (70–90%) of patients3.
Q18-3 How are pediatric/adolescent patients with type 1
diabetes to be treated?
• The goal of treatment consists of preventing diabetic compli-
cations through glycemic control as well as maintaining the
patient’s social and mental wellbeing1,2.
• In pediatric/adolescent patients with type 1 diabetes, insulin
injection therapy is indispensable and is therefore to be initi-
ated immediately after the diagnosis has been established1,2.
• MNT in pediatric/adolescent patients with type 1 diabetes is
not primarily intended to restrict the energy intake but
rather to ensure the age- and gender-speciﬁc intake of energy
that is necessary and sufﬁcient for their normal development
and growth1,2.
• All types of sport are recommended as physical activity/exer-
cise for pediatric/adolescent patients with type 1 diabetes as
long as they have no advanced complications and their gly-
cemic control remains stable1,2.
• Hypoglycemia is likely to be associated with cognitive
impairment. However, hypoglycemia may not be recognized
in patients below 6–7 years of age and may therefore
become severe. Thus, countermeasures need to be taken
against hypoglycemia in these patients. It should also be
noted that persistent hyperglycemia is also associated with
cognitive impairment4.
Q18-4 How is type 2 diabetes diagnosed in pediatric/
adolescent patients?
• An oral glucose tolerance test (OGTT) using glucose (body
weight 9 1.75) g (ideal body weight may also be used; up to
a maximum of 75 g) is to be performed in pediatric/adoles-
cent patients and their diagnosis is to be made according to
the same glucose categories and diagnostic criteria that are
used in adult patients1.
Q18-5 How are pediatric/adolescent patients with type 2
diabetes to be treated?
• As in patients with type 1 diabetes, the goal of treatment
consists of preventing chronic diabetic complications through
glycemic control as well as in maintaining their social and
mental wellbeing1,5. Again, early intervention for multiple
risk factors is the key to preventing micro and macroan-
giopathy in these patients.
• MNT in pediatric/adolescent patients with type 2 diabetes is
not primarily intended to restrict the energy intake but
rather to ensure the age- and gender-speciﬁc intake of energy
that is necessary and sufﬁcient for their normal development
and growth1,5. In obese individuals, however, the energy
intake is to be limited to 90–95% of the intake required for
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their ideal body weight and to be nutritionally well-
balanced1,6, while increased physical activity/exercise in these
individuals is to primarily involve aerobic exercise, thus
increasing both their physical activity levels and their energy
consumption1,6.
• In patients with inadequate glycemic control despite MNT
and physical activity/exercise, pharmacotherapy is to be initi-
ated1,5. In patients with ketoacidosis or those with inadequate
glycemic control despite pharmacotherapy, insulin therapy is
to be initiated1,5. In patients with hypertension and dyslipi-
demia, appropriate therapy is to be implemented for these
conditions1,5.
Q18-6 How is neonatal diabetes diagnosed and treated?
• Neonatal diabetes is broadly classiﬁed into transient and per-
sistent phenotypes; their diagnosis entails testing for the
respective responsible genes7.
• Sulfonylureas (SUs) have been shown to be effective in treat-
ing patients with KCNJ11/ABCCB8 gene mutations and to
allow these patients to discontinue insulin therapy8,9.
Q18-7 How are pediatric/adolescent patients and their
families to be supported?
• Pediatric/adolescent patients are to be given optimal therapy,
even at school1,10.
• Pediatric/adolescent patients are to participate in all school
events and school administrators are to ensure that their
schools provide support for their participation10.
• Given that mental/psychological factors have been shown to
signiﬁcantly affect the patient’s diabetes management and
prognosis, mental/psychological counselling is to be offered
with sufﬁcient care given to addressing individual differences
in mental/psychological maturity11,12.
• Immediately after affected patients have been diagnosed,
their families are to be fully instructed on their diabetes as
well as the treatment policy decided on to address their indi-
vidual maturity10.
• Diabetes camps are intended to offer support for pediatric
patients to grow into independent adults and include medi-
cally designed and recreational programs1.
19 DIABETES IN OLDER ADULTS
Q19-1 What are the characteristics of diabetes in older adults?
• Older patients with diabetes are likely to be susceptible to
postprandial hyperglycemia and hypoglycemia and to be par-
ticularly vulnerable to hypoglycemia.
• In patients with diabetes, older age tend to be associated
with renal impairment, which makes older patients suscepti-
ble to drug interactions.
• In patients with diabetes, older age is often associated with
geriatric syndromes such as dementia/cognitive impairment,
depression and sarcopenia.
CQ19-2 Is glycemic control effective in suppressing vascular
complications in older patients with diabetes? (Figure 7)
• Given that hyperglycemia is a risk factor for both diabetic
micro- and macroangiopathy in older patients as well,
appropriate glycemic control is to be implemented in these
patients1,2.
(Grade A by consensus: 100% agreement)
Q19-3 Are hyperglycemia and hypoglycemia risk factors for
cognitive impairment, dementia, decreased activities of daily
living (ADL) and depression in older patients?
• Hyperglycemia and severe hypoglycemia are risk factors for
cognitive impairment and dementia in older patients3,4.
• Hyperglycemia is a risk factor for sarcopenia, falls and
depression in older patients5, while decreased HbA1c6 and
hypoglycemia7 are associated with an increased risk of falls
in these patients.
• Given that there is no clear evidence to show that reducing
glucose levels leads to the prevention of dementia8 or
decreased ADL6, tight glycemic control should not be imple-
mented in older patients.
Q19-4 Is MNT effective for achieving glycemic control in older
patients with diabetes?
• MNT has also been shown to be useful for correcting hyper-
glycemia, dyslipidemia, obesity in older patients.
CQ19-5 Is physical activity/exercise effective for achieving
glycemic control and maintaining the ADL and cognitive
function of older patients with diabetes?
• Physical activity/exercise (i.e., routine physical activity and
walking) has been shown not only correct metabolic disorders
but also improve the life prognosis, reduce cardiovascular dis-
ease, maintain ADL, and suppress cognitive impairment9.
(Grade A: 100% agreement)
• Resistance training has been shown to increase the lean body
mass and muscle strength and improve glycemic control in
older patients with type 2 diabetes10.
(Grade B: 100% agreement)
Q19-6 What are the precautions in implementing glucose-
lowering therapy in older patients?
• Older patients receiving glucose-lowering agent(s) are to be
monitored for associated adverse events such as hypo-
glycemia and their families and caregivers are to be
instructed on nonspeciﬁc symptoms of hypoglycemia and
how to handle them as well as how to deal with sick days.
• The glucose-lowering agents that are to treat older patients
are to be chosen with consideration given to their physical
and cognitive function, socioeconomic status, adherence and
their (or their caregiver’s) wishes and preferences.
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• The renal function of older patients is to be regularly
assessed and their medications are to be replaced or their
doses adjusted accordingly.
Q19-7 Are hypertension and dyslipidemia risk factors for
other complications in older patients with diabetes?
• Hypertension is likely to be a risk factor for micro- and
macroangiopathy and dyslipidemia is likely to be a risk
factor for macroangiopathy in older patients with
diabetes.
20 ACUTE METABOLIC COMPLICATIONS OF DIABETES,
SICK DAYS, AND INFECTIOUS DISEASES
Q20-1 How is diabetic ketoacidosis (DKA) diagnosed and
treated?
• Diabetic ketoacidosis (DKA) is deﬁned as a state that occurs
as a consequence of inadequate insulin action and increased
insulin-counterregulatory hormone secretion and which
requires emergency attention due to associated hyper-
glycemia (>250 mg/dL [13.9 mmol/L]), ketosis (increased b-
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Figure 7 | Glycemic targets (HbA1c values) for older patients with diabetes. For older patients, the glycemic target is to be determined for each patient
by taking into account his/her age, duration of diabetes, risk of hypoglycemia, and any support available to the patient, as well as the patient’s cognitive
function, basic/instrumental activities of daily living (ADL), and comorbidities/functional impairments, while noting the potential risk of hypoglycemia
that increases with age in each patient. (1) Refer to the Japan Geriatrics Society website11,12, for the evaluation of the cognitive function, basic ADL (e.g.,
self-care abilities such as dressing, transferring, bathing, and toileting), and instrumental ADL (e.g., the patient’s ability to maintain an independent
household by performing activities such as shopping, meal preparation, taking medication, and handling finances). In end-of-life care, priority is to be
given to preventing significant hyperglycemia and subsequent dehydration and acute complications through appropriate therapeutic measures. (2) As
in other age groups, the glycemic target for preventing diabetic complications in older patients with diabetes is set to <7.0%. However, this can be set
to <6.0% for those who are thought to be likely to achieve glycemic control through MNT and/or physical activity/exercise alone or those who are
likely to achieve glycemic control with drug therapy without adverse reactions, or 8.0% for those in whom intensifying therapy may prove difficult. In
either case, no lower limit is specified for the glycemic target. A glycemic target of <8.5% may be allowed in patients who are thought to be in
category III and therefore at risk of developing adverse reactions to multi-drug combination therapy or in those with serious comorbidities or poor
social support. (3) In patients in whom priority should be given to preventing the onset/progression of diabetic complications due to their duration of
disease, the glycemic target or its lower limit may be set for each older patient with appropriate measures in place to prevent severe hypoglycemia.
Current treatments are to be continued in those who are <65 years of age, even when their HbA1c values fall below their glycemic target or a lower
limit while on therapy; however, care needs to be taken to monitor these patients for potential severe hypoglycemia. Glinides may be classified as
drugs that are unlikely to be associated with severe hypoglycemia, as the onset of severe hypoglycemia varies depending on the type and amount of
glinide used in a particular patient relative to the patient’s glucose level. [Colour figure can be viewed at wileyonlinelibrary.com]
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• Patients presenting with DKA are to be appropriately man-
aged with normal saline-based ﬂuid and electrolyte (e.g.,
sodium chloride and potassium) replacement as required1.
• As a rule, acidosis is not to be corrected in patients with
DKA1,2.
• Patients presenting with DKA are to be given regular insulin
as continuous intravenous insulin infusions1,2.
• The use of bolus insulin injection in children is associated
with the risk of cerebral edema and is not recommended3.
Q20-2 How is a hyperosmolar hyperglycemic state (HHS)
diagnosed and treated?
• A hyperosmolar hyperglycemic state (HHS) is associated
with hyperglycemia (>600 mg/dL [33.3 mmol/L]) and hyper-
osmolarity (effective osmolality, >320 mOsm/L) and poten-
tially mild ketosis (if present) but not severe ketoacidosis
(arterial blood pH >7.30; HCO3
-, ≤18 mEq/L)2.
• Patients presenting with HHS are to be appropriately man-
aged with normal saline-based ﬂuid and electrolyte replace-
ment as required2.
• As in DKA, patients presenting with HHS are to be given
regular insulin as continuous intravenous insulin infusions2.
Q20-3 How is lactic acidosis (LA) diagnosed and treated?
• Lactic acidosis (LA) is deﬁned as a state of metabolic acidosis
(arterial blood pH, <7.35) due to the presence of a markedly
increased lactic acid concentration (≥5.0 mmol/L) resulting
from the overproduction or metabolic dysregulation of lactic
acid and requires emergency attention4.
• Although LA is reported in patients receiving biguanides, the
majority of these cases occur in patients for whom bigua-
nides should have been contraindicated or used with cau-
tion5,6.
• Patients with LA should be treated for any underlying dis-
ease4.
• In patients with LA, sufﬁcient tissue blood ﬂow and oxy-
genation should be ensured with oxygen supplementation,
artiﬁcial respiration, extracellular ﬂuid replacement or vaso-
pressor therapy, as required4.
Q20-4 How is hypoglycemia managed?
• Patients exhibiting hypoglycemic symptoms, such as palpita-
tion, sweating, weakness or a decreased level of conscious-
ness, or those with a usual glucose level of <70 mg/dL
(3.9 mmol/L) should be diagnosed as having hypoglycemia
and managed accordingly7.
• Patients with hypoglycemia should be managed with oral
carbohydrates (equivalent to glucose 5–10 g), intravenous
glucose infusion (equivalent to glucose 10–20 g), or muscular
glucagon injection. Hypoglycemia may recur or be pro-
longed, even after the resolution of symptoms and therefore
needs to be closely monitored and managed8.
Q20-5 Are any infections typically associated with diabetes?
• Infections such as emphysematous cholecystitis, organ or soft
tissue abscesses, rhinocerebral mucormycosis, malignant
external otitis, emphysematous cystitis, emphysematous pyeli-
tis, necrotizing fasciitis and Fournier’s gangrene tend to have
diabetes as an underlying disease9.
Q20-6 How is glycemic control managed during infection?
• Diabetes is associated with decreased multinuclear neutrophil
migration, adhesion, phagocytic and bactericidal capacity.
Thus, infections tend to persist and become severe in
patients with poor glycemic control.
• Hyperglycemia should be treated with insulin therapy in
patients with a severe infection7,10,11. These patients must
also be managed not only with ﬂuid replacement and con-
tinuous intravenous insulin infusion, but also with immediate
treatment of any underlying disease responsible for hyper-
glycemia from an early stage onwards (the primary infection
site and the causative bacteria are to be identiﬁed and appro-
priate agents are to be chosen for the pathogen)11.
Q20-7 Is vaccination recommended in patients with diabetes?
• Inﬂuenza vaccination is recommended for patients with dia-
betes12.
• Pneumococcal vaccination is recommended for patients with
diabetes13.
Q20-8 How are sick days to be managed?
• Patients with diabetes should be encouraged to establish a
connection with healthcare facilities ahead of time to ensure
that they will be available for consultation during sick days14.
• Patients with diabetes are to be instructed not to discontinue
oral hypoglycemic agents or insulin without their physicians’
instruction14.
• When they have any problems with eating, patients with dia-
betes are to be encouraged to consult healthcare facilities
early and to receive appropriate instructions14.
• Care is to be taken to make sure that patients with diabetes
have a sufﬁcient water intake to prevent potential dehydration
and that they consume a sufﬁcient amount of easily digestible
carbohydrates (e.g., porridge, noodles and fruit juice) to
ensure a sufﬁcient intake of energy14 during sick days.
• Patients with diabetes are to be instructed to self-monitor
their glucose levels and to have their ketone body levels mea-
sured as frequently as possible during sick days14.
21 PREVENTION OF TYPE 2 DIABETES
Q21-1 How are patients assessed to determine their risk of
diabetes?
• Various risk factors have been identiﬁed for diabetes, and a
risk model (risk scores) is currently being developed for type
2 diabetes in Japanese1–3.
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Q21-2 Are obesity and changes in body composition
associated with the risk of type 2 diabetes?
• Obesity and abdominal obesity4, weight gain5,6, and low
birthweight7,8 are associated with an increased risk of dia-
betes.
Q21-3 Are physical activity and exercise habits associated
with the risk of diabetes?
• Strenuous physical activity in daily living9, aerobic exercises
such as walking10 and exercise habits such as resistance-exer-
cise training11,12 are associated with a decreased risk of dia-
betes.
Q21-4 Is the total energy and nutrient intake associated with
the risk of diabetes?
• Modiﬁcation of dietary habits focusing on optimization of
the total energy intake is crucial to prevent type 2 diabetes13–
15. An insufﬁcient intake of dietary ﬁbers has been shown to
be a risk factor for type 2 diabetes16,17.
Q21-5 Does the intake of alcoholic and other beverages affect
the risk of type 2 diabetes?
• Evidence from observational studies shows a U-shaped cor-
relation between the intake of alcohol and the risk of dia-
betes18,19. Thus, the intake of alcohol is to be limited to
within a reasonable range (equivalent to 20–25 g of ethanol
per day)20–22. The intake of soft drinks23,24 has been shown
to be associated with an increased risk of diabetes. While the
intake of coffee is highly likely to have a preventive effect
against the development of diabetes, the available evidence to
support this is not strong enough to include it among the
recommendations.
Q21-6 Do smoking and smoking cessation affect the risk of
type 2 diabetes?
• Smoking is an established risk factor for diabetes25. Smoking
cessation is temporarily associated with increased risk of dia-
betes due to associated weight gain but is associated with a
decreased risk of diabetes over the long term26,27.
Q21-7 Are psychosocial factors, such as stress and working
environment, associated with the risk of type 2 diabetes?
• Mental stress28 and depressive tendencies (depression)29,30
are associated with an increased risk of diabetes. Working
environmental factors, such as short sleep duration31 and
shift work32, are also risk factors for diabetes.
CQ21-8 Does intervention with lifestyle modiﬁcation prevents
type 2 diabetes?
• Intervention with lifestyle modiﬁcation focused on adjust-
ment of diet and exercise habits has been shown to be
effective in preventing type 2 diabetes13–15,33–35.
(Grade A: 100% agreement)
Q21-9 Does pharmacotherapy prevent type 2 diabetes?
• Biguanides36, a-glucosidase inhibitors37,38, and thiazolidine-
diones39 are shown to be effective in preventing diabetes (In
Japan, only voglibose has been covered by health insurance
for use in patients with impaired glucose tolerance [IGT]
who are considered to be at high risk of cardiovascular
disease)40.
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APPENDIX 1
① Diabetes and Cancer
Report of the JDS/JCA Committee on Diabetes and Cancer
Given that there is a clear association between diabetes and the risk
of cancer1–9, experts from the Japan Diabetes Society (JDS) and
the Japanese Cancer Association (JCA) launched a Joint Commit-
tee on Diabetes and Cancer, published a report in 2013 and pro-
vided its recommendations for physicians and other healthcare
providers as well as for the general public, including patients10.
The cancer risk in patients with diabetes
A pooled analysis of eight cohort studies conducted in Japan
reported that the hazard ratio (HR) for the total cancer risk
among patients with diabetes was 1.19 in comparison to those
without, with the HR among men being 1.19 (95% conﬁdence
interval [CI], 1.12–1.25) and that among women being 1.19
(95% CI, 1.12–1.27)11. The mechanisms through which diabetes
is likely to promote oncogenesis include insulin resistance and
associated hyperinsulinemia, hyperglycemia, and chronic
inﬂammation. However, whether diabetes is a causal risk factor
for cancer remains to be elucidated.
Glucose-lowering agents and cancer risk
At present, the association between glucose-lowering agents and
the cancer risk remains to be fully clariﬁed. Thus, it is thought to
be preferable that priority be given to maximizing the beneﬁts of
favorable glycemic control with these agents, with due considera-
tion given to the warnings contained in their package inserts.
② Diabetes and Bone Mineral Metabolism
The risk of bone fracture in patients with diabetes
The relative risk of proximal femoral fracture is increased 3- to
7-fold in patients with type 1 diabetes and 1.3- to 2.8-fold in
patients with type 2 diabetes.
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Bone strength consists of two factors: bone mineral density
(BMD) and bone quality.
The bone mineral metabolism in type 2 diabetes is character-
ized by increased BMD and impaired bone quality.
Anti-diabetic agents and bone mineral metabolism
A meta-analysis demonstrated that thiazolidinedione (TZD)
treatment was associated with a 1.45-fold increase in the risk of
fracture12. A further analysis indicated that TZDs were associ-
ated with a 2.23-fold increase in the risk of fracture in women
but not in men13.
There is no consensus on the risk of fracture associated with
the use of insulin, DPP-4 inhibitors, GLP-1 receptor agonists,
or metformin.
The US Food and Drug Administration (FDA) reported in
its Drug Safety Communication that an SGLT-2 inhibitor,
canagliﬂozin, has been associated with decreased BMD and an
increased risk of fracture in comparison to a placebo14.
The use of anti-osteoporosis agents in diabetes
The lumbar and femoral neck BMD have been reported to




Pancreas transplantation has become available as a radical ther-
apy for severe diabetes, particularly type 1 diabetes.
Pancreas transplantation is broadly divided into simultaneous
pancreas and kidney transplantation (SPK), pancreas-after-kid-
ney transplantation (PAK), and pancreas transplantation alone
(PTA). SPK accounts for >80% of all pancreas transplants per-
formed in Japan and the rest of the world.
Data from the 210 brain-dead and non-heart-beating donor
pancreas transplants performed in Japan as of the end of 2014
demonstrated a 5-year graft survival rate of 95.8%, with the 5-
year pancreas and kidney survival rates of 70.4% and 89.2%,
respectively.
The ﬁrst living donor pancreas transplant in Japan was per-
formed in January 200416; and as of the end of 2014, a total of
27 transplants had been performed.
Islet transplantation
Islet transplantation is a form of tissue transplantation that
involves the injection of islets isolated from donor(s) into the
recipient’s portal vein and is thus less invasive than pancreas
transplantation.
In Japan, 34 islet transplantation procedures (from non-
heart-beating donors) were performed in 18 patients (male,
n = 5; female, n = 13) between 2004 and 2007; the procedures
were performed in accordance with the Edmonton protocol17.
Among these patients, 8, 4 and 6 patients received one, two
and three transplants, respectively. One of the patients who
received two transplants and 2 who received three transplants
were shown to have achieved a temporary withdrawal of insu-
lin therapy18,19.
The 1-, 2- and 3-year graft survival rates in these patients
were 72.2%, 44.4%, and 22.2%, respectively. The 1-year graft
survival rate among those who received multiple transplants
was 100%18,19.
④ J-DOIT 1, 2, and 3, JDCP Study and J-DREAMS
On the ‘Strategic Research Projects for Prevention of Diabetes’
In 2005, the Ministry of Health, Labor and Welfare (MHLW)
of Japan launched a framework for the Health Frontier Strate-
gic Plan as a large-scale MHLW research project. Thus, as a
part of the project, the Strategic Research Projects for Preven-
tion of Diabetes was initiated, consisting of three research
themes (J-DOIT 1, 2, and 3, respectively).
Japan Diabetes Outcome Intervention Trial 1 (J-DOIT 1)
To prove that intensive lifestyle intervention is effective in pre-
venting the onset of diabetes in patients at high risk of develop-
ing diabetes in real-world settings (i.e., facilities offering health
check-ups and health instruction services), a cluster randomized
trial entitled, the ‘Japan Diabetes Outcome Intervention Trial 1
(J-DOIT 1)’, was conducted between March 2007 and March
2012.
Japan Diabetes Outcome Intervention Trial 2 (J-DOIT 2)
The ‘Japan Diabetes Outcome Intervention Trial 2 (J-DOIT 2)’
was an interventional study intended to address how best
decrease treatment and consultation interruptions by patients
with type 2 diabetes.
The interventional measures implemented in the study
included encouraging patients who were being treated by their
family physicians to seek treatment/consultation, providing
healthcare instructions, and providing their family physicians
with assistance in their treatment/consultations. The results of
the study demonstrated that treatment/consultation interrup-
tions had been decreased by 63%, suggesting that the interven-
tional measures were signiﬁcantly effective in decreasing
treatment/consultation interruptions.
J-DOIT 3 (the Japan Diabetes Optimal Integrated Treatment study
for three major risk factors of cardiovascular diseases (J-DOIT 3)
The J-DOIT3 (Japan Diabetes Optimal Integrated Treatment
study of three major risk factors for cardiovascular diseases [J-
DOIT 3]) aimed to investigate whether or not integrated tight
glycemic control, blood pressure control and lipid control may
reduce the onset of macroangiopathy among patients with type
2 diabetes.
J-DOIT 3 was conducted from 2006 until March 2016. The
study involved a total of 81 sites nationwide and enrolled a
total of 2,532 type 2 diabetes patients who were considered to
have a high risk of developing macroangiopathy. The patients
were randomly allocated to receive intensive therapy or conven-
tional therapy.
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JDCP study
The JDCP study was a large-scale prospective observational
study of Japanese patients with type 1 and type 2 diabetes. The
study was conducted to identify the risk factors that patients
with type 1 and 2 diabetes develop during follow-up.
The JDCP study enrolled a total of 6,338 patients of 40–
74 years of age who were being treated at participating sites
nationwide between June 2007 and November 2009. The pri-
mary endpoints of the study included the onset/progression of
nephropathy, retinopathy, neuropathy, macroangiopathy, and
periodontal disease.
J-DREAMS
The Japan Diabetes comprehensive database project based on
an advanced electronic medical record system (J-DREAMS) is a
large-scale database project that was launched by the Japan
Diabetes Society (JDS) and the National Center for Global
Health and Medicine (NCGM).
Given that all JDS-qualiﬁed educational facilities for certiﬁ-
cated diabetologists are participating and that hundreds of
thousands of patients are expected to be registered, this study
will be expected to show the control status of each parameter,
the frequency of complications, and the correlations between
complications and the glycemic control status or therapeutic
agents in patients treated by certiﬁed diabetologists.
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